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SUMMARY 
Cell polarity describes the asymmetric distribution of proteins, RNA, organelles and 
lipids. One of the best studied models of polarity are epithelial cells. They form the barriers that 
separate and protect the organism from the outside environment. Establishment and maintenance 
of polarity is ensured through a highly complex network of proteins and lipids that mediate 
asymmetry through trafficking processes and reorganization of the cytoskeleton. One of the key 
players in polarity are phosphoinositides, phosphorylated forms of the lipid phosphatidylinositol. 
In this thesis I investigated the role of one such phosphoinositide, PI(3)P, on cellular polarity and 
immunity in human intestinal epithelial cells. 
In my work I used established methods to evaluate the role of PI(3)P in human intestinal 
epithelial cells. These three methods were (1) the use of specific inhibitors targeting VPS34 (2) 
the development of cell lines depleted of kinases and phosphatases needed for PI(3)P biogenesis 
and (3) on demand depletion of PI(3)P from endosomes using a chemical dimerizer system. Each 
of these methods were evaluated both for their ability to modulate PI(3)P levels and for their 
impact on cellular polarity and immune response. While I could demonstrate that all three 
methods successfully modulated PI(3)P levels the chemical dimerizer (AP21967) interferes with 
polarity and immunity itself and we require a new dimerizer before conclusions can be made 
using this method. Interestingly, I determined that reduced PI(3)P levels, either by chemical 
inhibition or knock-down of the kinase VPS34, impaired cellular polarity in T84 cells indicating 
a critical role of PI(3)P in the polarity program. Additionally, knock-down of the PI(3)P 
metabolizing enzymes VPS34 and MTM1 showed interesting results for IFNλ production upon 
reovirus infection. IFNλ production in MTM1 and VPS34 knock-down cells is increased and 
decreased respectively. This could be due to the previously reported PI(3)P dependent TLR3 
sorting adaptor WDFY1 and should be further investigated.  
In parallel I also created a novel viral vector system in our lab. This viral vector is based 
on the BacMam system which are baculovirus based vectors with a large cargo capacity. The 
BacMam was initially modified with an S/MAR sequence to allow for its persistence in cells. The 
vector was then further modified to allow expression of reporter genes. Both vectors were shown 
to be fully functional and will provide a valuable tool for future projects.  
Zusammenfassung 
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ZUSAMMENFASSUNG 
Zellpolarität bezeichnet die asymmetrische Verteilung von Proteinen, RNS, Organellen 
und Lipiden. Epithelzellen sind eines der am besten untersuchten Modelle für Polarität. Sie bilden 
eine Barriere die das Innere des Organismus vor der Außenwelt schützt. Ein hochkomplexes 
Netzwerk aus Proteinen und Lipiden stellt Polarität durch asymmetrische Transportvorgänge und 
Veränderungen im Zytoskelett her und erhält sie aufrecht. Phosphoinositole sind Lipide und eine 
der wichtigsten Komponenten in diesem Netzwerk. In dieser Arbeit wurde die Rolle eines dieser 
Lipide, PI(3)P, in der Polarität und der Immunantwort in menschlichen Darmepithelzellen 
untersucht. 
Um die Rolle von PI(3)P in menschlichen Darmepithelzellen zu untersuchen wurden drei 
gängige Methoden verwendet: (1) Spezifische Inhibitoren gegen die Kinase VPS34, (2) Knock-
down von VPS34 und MTM1, Enzymen die an der Biogenese von PI(3)P beteiligt sind, und (3) 
Reduzierung des endosomalen PI(3)P mit einem System zur chemisch-induzierten Dimerisierung 
von Proteinen. Diese Methoden wurden in auf ihre Fähigkeit PI(3)P Level zu verändern hin 
untersucht. Während alle drei Methoden die PI(3)P Level veränderten, zeigte sich, dass der 
Dimerisierungsinduktor AP21967 sowohl Polarität als auch die Immunantwort negativ 
beeinflusst. Wir benötigen einen neuen Dimerisierungsinduktor bevor wir diese Methode 
tatsächlich nutzen können. Eine Verringerung der PI(3)P Level, entweder durch Inhibierung oder 
Knock-down der Kinase VPS34, hatte eine Beeinträchtigung der Polarität und der Immunantwort 
zur Folge. Das deutet auf eine entscheidende Rolle von PI(3)P in diesen Prozessen hin. Knock-
down von VPS34 oder MTM1, resultierte in interessanten Ergebnissen bei der IFNλ 
Immunantwort auf eine Reovirus Infektion. Diese ist nach MTM1 Knock-down erhöht und nach 
VPS34 Knock-down verringert. Das könnte durch die bereits publizierte Rolle des TLR3 
Adapters WDFY1 zustande kommen und sollte genauer Untersucht werden. 
Zudem wurde parallel ein neuer viraler Vektor in unserem Labor etabliert. Dieser basiert 
auf BacMam, virale Vektoren basierend auf Baculoviren die eine sehr hohe 
Verpackungspakazität haben. Das BacMam System wurde mit einer S/MAR Sequenz modifiziert 
die es dem Virus erlaubt dauerhaft in Zellen zu verbleiben. Dieser Virus wurde dann weiter 
verändert um die Expression von Reporter Genen zu erlauben. Beide Vektoren sind funktional 
und werden von großer Hilfe für zukünftige Projekte sein.  
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1 INTRODUCTION 
1.1 EPITHELIAL POLARITY 
Cellular polarity is a term that describes the asymmetric distribution of cellular components 
such as proteins, lipids, RNA and even whole organelles1. It is a phenotype that is found in many 
cells. Commonly studied examples include neurons (axon - dendrites), migrating cells 
(directional polarization with leading and trailing edge), asymmetrically dividing stem cells, and 
epithelial cells (apico-basal axis)1,2. Monolayered epithelia have an apical site facing the outside, 
e.g. lumen of the gut or urinary tract, and a basolateral site with which the cells are in contact 
with one another and the extracellular matrix on the inside of the body3,4.  
The intestinal epithelium is composed of five different cell types that arise from a common 
stem cell niche. The vast majority of cells are the absorptive enterocytes5. Besides their barrier 
function, they are involved in nutrient uptake and secretion of antimicrobial peptides (AMPs)6,7. 
These cells are what we will focus on in this thesis and refer to them as intestinal epithelial cells 
(IECs). In addition to the enterocytes there are the hormone secreting enteroendocrine cells, 
mucus secreting goblet cells, Paneth cells that secrete AMPs, and microfold cells (M-cells) that 
sample antigens by transcytosis to underlying immune cells7–10. One of the primary functions of 
the intestinal epithelium is that of a physical barrier. It separates the inside of the body from the 
lumen of the intestine and its microbiome11. To fulfill this task, the cells have to form a tight 
monolayer of polarized cells. This epithelial polarity is established and maintained by an intricate 
network of proteins and lipids termed the epithelial polarity program (EPP)12. This part of the 
introduction will provide a general overview of the EPP without the lipids which will be 
discussed in section 1.3. 
To investigate how apico-basal polarity is initially established, epithelial cells can be grown 
in an artificial extracellular matrix (ECM) either composed of collagen or Matrigel, a commercial 
ECM secreted by a murine tumor cell line13,14. Single cells will start dividing and ultimately form 
a three dimensional structure named spheroid or cyst (Figure 1)15. The most common model for 
mammalian epithelial cells are Madin-Darby canine kidney (MDCK) cells. When MDCK cells 
are grown as spheroids, they initially express the apical marker protein Podocalyxin everywhere 
in the plasma membrane (Figure 1 A). In the two cell stage they display an inverted polarity 
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phenotype. The apical marker Podocalyxin faces the ECM while the basolateral marker β-catenin 
is localized to the plasma membrane where both cells are in contact (Figure 1 B). At this contact 
site the first cell-cell connections form, which is known as the apical membrane initiation site 
(AMIS). As cells grow and divide, polarity markers will start to relocate to their correct 
membrane domain and Podocalyxin can be found in the pre-apical patch (PAP) where a small 
lumen forms (Figure 1 C)14,16. Upon further cell divisions this small lumen becomes a single, 
large lumen in the center of the spheroid (Figure 1 D). 
 
Figure 1: Schematic of MDCK spheroid formation. A) Single cell not showing signs of polarization. Podocalyxin is found 
everywhere plasma membrane. B) Two cell stage with inverted polarity. The apical marker Podocalyxin faces the extracellular 
matrix and the basolateral marker β-catenin localizes to the membrane contact site. This is the membrane initiation site (AMIS) 
forms. C) Small cell aggregate where pre-apical patch (PAP) has formed. Polarity markers show correct localization. D) Fully 
formed spheroid with a single, large lumen. Data was adapted from14,16,17. 
Even before the pathways establishing apico-basal polarity were elucidated as much as 
they are today, it was known that MDCK cells secrete laminin at their basal side to form a 
basement membrane18. It has been shown that the GTPase Rac1 is a key player in establishing 
apico-basal polarity by assembling a laminin basement membrane at the basal pole 13. While 
Rac1 is a key player, there are a large number of other proteins involved. Some of the most 
important proteins can be divided into four different groups which will be mentioned here briefly. 
First there are the apical proteins of the Crumbs (CRB) group: Crumbs itself, membrane 
palmitoylated protein 5 (MPP5, also known as PALS1), and PALS1-associated tight-junction 
homologue (PATJ)12. Members of the Scribble (SCRIB) group, SCRIB, Discs-large homologue 
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(DLG) and Lethal giant larvae (LGL), show a polarized distribution to the lateral site of cells12. 
Next there are the PAR proteins, which contains PAR1, 3, 4, 5, 6, atypical protein kinase C 
(aPKC), and the GTPase Cdc4212. PAR3, PAR6, Cdc42, and aPKC are usually considered to be 
apical determinants19. PAR1 and PAR4 are localized in the basolateral domain but still are not 
considered to be part of either an apical or basolateral complex and PAR5 is found in the 
cytoplasm19. In Drosophila there is also the Coracle group of proteins which in addition to 
Coracle itself includes Moesin, Yurt, Neurexin IV, and the Na+, K+-ATPase12. Giving that the 
p58 subunit of the Na+, K+-ATPase is used as a basolateral marker in MDCK cells, one could 
assume that the Coracle is used in other organisms besides Drosophila20,21. Interestingly, only 
Crumbs, Neurexin IV, and the Na+, K+-ATPase are transmembrane proteins. The other proteins 
mentioned above are kept in their respective domain by interaction with other polarity proteins or 
membrane proteins12. Regulation of polarity requires a complex interplay between all of these 
components. 
PAR3 is one of the earliest proteins found in the future apical domain. It is involved in 
targeting the Cdc42-PAR6-aPKC complex and PALS1 to the apical side. It also helps recruit E-
cadherin to form adherens junctions19. When polarization progresses, PAR3 itself becomes a 
target for aPKC phosphorylation and exclusion from the apical domain, possibly mediated by 
PAR5 which has been shown to mediate the exclusion of PAR3 from the basal domain after 
PAR1 phosphorylation22,23. This complex interplay allows PAR3 to be localized at a narrow area 
just between the apical and basolateral domains at the adherens junctions or tight-junctions14,24. 
This mechanism of mutual exclusion is used by several other proteins as well, e.g. aPKC 
phosphorylation of PAR1 and LGL to exclude them from the apical domain25,26.  
Besides cytoplasmic proteins that are kept in their respective domains by the exclusion 
mechanisms described above, it is important that cells have intracellular transport mechanisms 
targeting vesicular carriers to the correct domain. This requires rearrangement of the trafficking 
machinery which includes a variety of endosomal compartments such as the apical- and basal 
sorting endosome (ASE, BSE), the apical recycling endosome (ARE) and the common recycling 
endosome (CRE) in addition to the common components involved in vesicular trafficking such as 
late endosomes, lysosomes, and Golgi apparatus27. This system is different from non-polarized 
cells as can be seen for Rab11a. Rab11a is involved in transferrin recycling only in nonpolarized 
MDCK cells but not after polarization when the transferrin receptor is localized to the basolateral 
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site28. The role of the Rab11a compartment in selective apical delivery of cargo has also been 
shown in human polarized intestinal epithelial cells (Caco-2)29. Therefore it is assumed that 
Rab11a switches from general recycling to predominantly apical recycling (ARE). This change is 
not absolute as the trafficking of E-cadherin to the lateral site requires Rab11a endosomes30. 
Rab35 is another protein that has been shown to be involved in establishing polarity by apical 
trafficking, and is involved in bringing Podocalyxin to the AMIS31. These vesicles not only 
contained Podocalyxin but also Crumbs3, Cdc42, aPKC, and Rab11 all of which are important 
polarity proteins defining the apical pole31. However, each polarized system is unique and will 
show unique factors required for the establishment of polarity32. 
One of the early determinants trafficked to the apical side is the polarity protein Crumbs, 
which is trafficked to the apical site through Rab11-positive vesicles19,33. In Drosophila, surface 
levels of Crumbs have to be tightly controlled by surface delivery and endocytosis. If endocytosis 
is disrupted by targeting the clathrin adaptor AP-2, the apical domain expands and normally 
monolayered epithelia are more likely to become multilayered34.  
Cdc42 was so far introduced as being important for establishing the apical membrane 
domain. But it was also shown that it is involved in the exit of apical as well as basolateral cargo 
from the trans-Golgi-network (TGN) in MDCK cells35. Another group verified the role of Cdc42 
in basolateral trafficking by showing hat loss of Cdc42 in MDCK cells resulted in the loss of 
basolateral polarity while apical polarity was not impaired36.  
One prerequisite of polarity are tight junctions. Tight-junctions separate the apical from 
the basolateral domain and prevent diffusion between both domains37. They are composed of 
transmembrane proteins (claudins, occludin and junctional adhesion molecules (JAMs)), as well 
as many interacting proteins such as zonula occludens (ZO) proteins bridging it with the actin 
cytoskeleton37. The ability of tight junctions to prevent passive diffusion across the monolayer 
can experimentally be measured by the trans-epithelial electrical resistance (TEER). It was shown 
that aPKC isotype specific interacting protein (ASIP)/PAR3/aPKC positively regulates tight 
junction formation in MDCK cells which can be shown by an increased TEER38. Later another 
group showed that loss of PAR3 in MDCK cells disrupts assembly of tight junctions in an Rac-
dependent pathway39. Overexpression of dominant-negative Rac or knock-down of its guanine 
nucleotide exchange factor (GEF) Tiam1 in cells missing PAR-3 improved tight-junction 
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formation39. Other parts of the epithelial polarity program are involved in tight-junction 
formation as well. Expressing an inactive PAR6 mutant in murine cancer cells induced ZO-1 
structures and reduced their metastasis to the lung when implanted in BALB/c mice and 
exogenous expression of Crumbs3 induces tight junction formation in the epithelial cell line 
MCF10A, which normally do not have tight junctions40,41. 
Research over the last decades has helped us to get a better understanding of how 
epithelial polarity is established and maintained. It has become obvious that it is the result of 
highly complex and interdependent protein complexes and a rearranged endosomal system all of 
which participate in defining distinct apical and basolateral plasma membrane domains, cell-cell 
junctions, and providing specific, polarized trafficking routes. 
1.2 IMMUNITY IN INTESTINAL EPITHELIAL CELLS 
To protect the host form the intestinal microbiome the epithelium works not just as a 
mechanical barrier but also as a platform to sense and combat viral or microbial infection. In this 
part I will give a short introduction into how IECs can sense infection and then briefly talk about 
the interplay between the microbiome and the intestinal epithelium. 
The cell’s intrinsic innate immunity is based on germ-line encoded pattern recognition 
receptors (PRRs) which can provide a first line of defense before the more specialized adaptive 
immune system can provide protection42. These sensors include the toll-like receptors (TLRs) and 
the retinoic acid inducible gene I (RIG-I)-like receptors (RLRs)42–44. All of these receptors 
recognize pathogen-associated molecular patterns (PAMPs) which are conserved structures found 
on microorganisms and viruses. Since they are not found on the host itself they allow a self – 
foreign differentiation42. 
All 10 TLRs encoded by the human genome have the same general structure. They have 
an extracellular domain composed of multiple leucine-rich repeats in a horseshoe shape that 
mediates pattern recognition. A transmembrane domain connects it to the intracellular Toll/IL-1 
receptor (TIR) domain to relay the signal into the cell42,45. TLRs can be subdivided according to 
their localization into cell surface TLRs (TLR1, 2, 4, 5, 6, 10) and endosomal TLRs (TLR3, 7, 8, 
9). While having similar structures, they recognize a wide variety of patterns. TLR2 together with 
TLR1 or TLR6 recognizes triacylated lipopeptides or diacylated lipopeptides respectively. Upon 
activation they signal via TIR Domain Containing Adaptor Protein (TIRAP) and Myeloid 
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Differentiation Primary Response 88 (MyD88) to stimulate nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) mediated production of proinflammatory cytokines46. 
TLR5 recognizes bacterial flagellin and signals via MyD88 and NF-κB like TLR2/1/646. Plasma 
membrane TLR4 together with MD2 is activated by bacterial lipopolysaccharide (LPS) and 
signals via TIRAP and MyD88 to stimulate NF-κB mediated inflammatory cytokine production. 
TLR4 is then taken up by the cell and signals from within the endosome via TIR-domain-
containing adapter-inducing interferon-β (TRIF) and TRIF-related adaptor molecule (TRAM) 
which continue to signal via NF-κB but also induce interferon regulatory factor 3 (IRF3) 
mediated type I interferon production46,47. TLR7 and TLR9 recognize single stranded RNA and 
unmethylated CpG sequences in DNA respectively. They signal from the late 
endosome/endolysosome compartment via MyD88 to induce proinflammatory cytokines and type 
I interferon through NF-κB and IRF7 respectively46. TLR3 signals the late 
endosomes/endolysosomes as well and upon recognition of double stranded RNA it induces 
inflammatory cytokines and type I interferon through NF-κB and IRF3 respectively in a TRIF 
dependent manner42,46. TLR10 differs from the other receptors described in that it was reported to 
act as a negative regulator of TLR signaling48,49. 
RIG-I like receptors are cytoplasmic proteins belonging to the family of DExD/H box 
RNA helicases. This group encompasses RIG-I, Melanoma Differentiation-Associated protein 5 
(MDA5), and laboratory of genetics and physiology 2 (LGP2)44. They all have zinc-binding C-
terminal domain (repressor domain) and a central helicase domain that mediates double stranded 
RNA binding. RIG-I and MDA5 also have N-terminal tandem caspase activation and recruitment 
domains (CARD) necessary for signaling. As LGP2 doesn’t have these CARD it can’t signal but 
rather has regulatory functions44. Once RIG-I or MDA5 bind their ligand, they can interact with 
their common adaptor mitochondrial antiviral signaling protein (MAVS). MAVS signals through 
multiple proteins including TNF receptor-associated factor 2 (TRAF2), TRAF3, and TRAF644. 
IRF3/7 and NF-κB then drive expression of type I and type III interferon as well as 
proinflammatory cytokines44. It was shown that despite its name, MAVS is also found on 
peroxisomes which have been identified as the primary signaling hub for the RLR induced type 
III interferon response50.  
The intestinal epithelium is in contact with the microbiome and needs to be able to 
tolerate commensals but mount an immune response to pathogens or when the epithelial barrier is 
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breached. This is especially important for surface expressed TLRs5. One hypothesis is that 
tolerance is achieved by predominantly expressing TLRs on the basolateral surface. There they 
only get into contact with their ligand if the epithelial barrier is breached and an immune 
response has to be mounted5. When TLR distribution in healthy intestinal tissue samples was 
compared with samples from ulcerative colitis (UC) and Crohn’s disease (CD) patients, an 
increase in TLR4 expression in both UC and CD patients was found. Furthermore, the TLR4 
signal was predominantly basolateral in healthy individuals and UC patients. In CD patients on 
the other hand a strong TLR4 signal at the apical pole was observed51. This points towards a role 
of TLR signaling in the inflammatory symptoms of CD patients as well as polarity in preventing 
inflammation in healthy individuals51. Also it was shown that the polarized human colon 
carcinoma cell line HCA-7 responds stronger to basal TLR5 stimulation than to apical 
stimulation52. Reduced expression of the sensor might help to achieve tolerance as well. While 
TLR4 was barely detectable in biopsies from healthy individuals, patients with ulcerative colitis 
or Crohn’s disease showed a strong upregulation51. As it is technically difficult to analyze the 
exact location of TLRs on the different intestinal epithelial cell types, these results have to be 
interpreted carefully. Also it might not be necessary that TLRs are strictly localized to one side. It 
was shown that the outcome of TLR9 signaling in intestinal epithelial cells depends on the site of 
stimulation. While basolateral stimulation of polarized HCA-7 cells invokes an NF-κB dependent 
immune response, apical stimulation resulted in accumulated IκBα which prevented NF-κB 
activation. It also conferred intracellular tolerance to subsequent TLR stimulations52. Furthermore 
they showed that basal TLR3 stimulation elicited a much stronger IL-8 response than apical 
stimulation52. As TLR9 and TLR3 are both endosomal, this would argue for the ability of cells to 
tell apart which site the stimulation came from and respond accordingly. This is further 
substantiated by data from our lab. When polarized T84 cells are infected with reovirus Type 3 
Dearing (T3D), which is mostly sensed by RIG-I, a site specific immune response is mounted 
(Figure 2). Infection from the basolateral site results not only in a stronger interferon λ response 
but also in a longer lasting response (Figure 2 A). Such a difference cannot be seen for interferon 
β1 (Figure 2 B). Data speaking against a strict localization of receptors to the basolateral site is 
further substantiated by observations that TLR signaling is indeed beneficial for the host. 
Examples include experiments with mouse models of inflammatory bowel disease (IBD). For 
example, mice lacking signaling by most TLRs (MyD88-/-) develop much more severe intestinal 
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inflammation53. Other experiments showed that Bacteriodes fragilis protected animals from 
experimental IBD in an TLR2 dependent manner53.  
While there is still much more work to do to gain a more complete understanding of the 
tolerance to the microbiome, work in our lab and from others indicates that the polarized 
phenotype of the intestinal epithelium is involved since both, the preferential localization of 
receptors to the basolateral site and the ability to distinguish which side the signal originates 
from, requires polarized cells. 
 
 
Figure 2: Immune response to reovirus Type 3 Dearing (T3D) infection in polarized intestinal epithelial cells. Polarized T84 
cells were infected with reovirus T3D from the apical or basal site. mRNA expression of interferon λ (A) and interferon β1 (B) 
were analyzed between 4 and 60 hours post infection. Experiment performed by Megan Stanifer.  
1.3 LIPIDS 
Cellular membranes are an essential pre-requisite of life. They form the borders of cells, 
protecting the cytosol from the extracellular space. This separation is what makes life possible. 
What started with a simple membrane surrounding the prokaryotic cytoplasm evolved into highly 
complex eukaryotic cells with numerous membranous organelles. These membrane separated 
compartments allow cells to spatially separate processes that require different environments or 
are incompatible with one another, e.g. the proton gradient over the mitochondrial membrane 
used for energy generation or the low lysosomal pH required for hydrolytic enzymes to work54,55. 
The major building blocks of all cellular membranes are lipids. While an all 
encompassing definition of lipids is difficult, the LIPID MAPS Classification System has defined 
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them as “hydrophobic or amphipathic small molecules that may originate entirely or in part by 
carbanion- based condensations of thioesters (fatty acids, polyketides, etc.) and/or by 
carbocation-based condensations of isoprene units (prenols, sterols, etc.)”56. Their classification 
system divides all lipid molecules into eight different categories (fatty acyls, glycerolipids, 
glycerophospholipids, sphingolipids, sterol lipids, prenol lipids, saccharolipids, and polyketides) 
that contain further subcategories57. Lipids found in membranes are amphiphilic molecules with a 
hydrophilic head group linked to a hydrophobic tail, most commonly glycerophospholipids58,59.  
1.3.1 PHOSPHOINOSITIDES 
Phosphatidylinositol (PI) belongs to the group of glycerophospholipids57. It is a minor 
component of cellular membranes making up between 5% and 10% of a cells lipids, although 
numbers as low as only 1.2% of all phospholipids were reported for human erythrocytes58–60. The 
structure of a dipalmitoyl phosphatidylinositol (PI(16:0/16:0)) as an example of PIs is shown in 
Figure 3. PI has an inositol ring (myo-inositol) as a hydrophilic head-group that is connected to 
the hydrophobic diacylglycerol (DAG) via a phosphodiester bond. The exact structure of DAG 
can vary in terms of fatty acid chain length or degree of saturation61. The relative quantity of such 
PI species can even change as has been shown in macrophages where activation is accompanied 
by a 300% increase in PI(20:4/20:4)62. Another way in which PI can participate in cellular 
signaling events is as lysophosphatidylinositol (LPI). This is produced by phospholipase A 
removing one of the fatty acid chains63. LPI has been shown to be the ligand for GPR55, a G-
protein coupled receptor which is implicated to be involved in various diseases such as cancer 
and type 2 diabetes63,64. LPI can bind GPR55 directly, making it a good example of how lipids 
provide more than a barrier function65. 
 
Figure 3: Phosphatidylinositol (PI) schematic.  Image depicts dipalmitoyl phosphatidylinositol as an example. Within cells 
different species of this lipid exist, differing in their side chain lengths and degree of saturation (number of double bonds). PI can 
be reversibly phosphorylated at the positions 3, 4, and 5 or the inositol ring (blue numbers) giving rise to a total of seven different 
PI-phosphates (phosphoinositides). Lipid structure was taken from the LIPID MAPS Structure Database (LMGP06010007)66. 
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But most of the time when speaking about different PI species it refers to differences in 
the phosphorylation pattern of the inositol ring. It can be reversibly phosphorylated at positions 3, 
4, and 5 which results in a total of seven different phosphatidylinositol phosphate species (PIPs) 
also known as phosphoinositides: PI(3)P, PI(4)P, PI(5)P, PI(3,4)P2, PI(3,5)P2, PI(4,5)P2, 
PI(3,4,5)P3
67
. The seven different phosphoinositides are not all equally abundant. Levels of 
PI(4,5)P2 for examples have been reported between 0.3 and 1.5 mol% of total phospholipids in 
murine BL/VL3 lymphoma cells and human erythrocytes respectively60,68. In Saccharomyces 
cerevisiae both PI(4)P and PI(4,5)P2 have been shown to make up between 1.5 and 2% of total PI 
each (PI + PIPs)69. Levels of PI(3,5)P2 are ususally lower. In S. cerevisiae this lipid was not 
detectable with a standard chloroform-methanol-HCl extraction. Only when cells were lysed with 
perchloric acid the recovery improved enough to allow for detection of basal PI(3,5)P2 levels 
which are 18 to 28 fold lower than the levels of PI(3)P, PI(4)P, and PI(4,5)P2
70. Another 
publication found that PI(3,5)P2 made up less than 0.2% of total PI while PI(3)P levels were at 
approximately 2.5% of total PI69. The large span in the reported abundance of phosphoinositides 
not only stems from the different cell types used, but also from the lipid extraction method, as 
PI(3,5)P2 only became detectable once the extraction method was modified
70. Also it is quite 
likely that the different detection methods play a role. Often phosphoinositides were labeled with 
[3H]-inositol, extracted and then separated and phosphoinositide levels analyzed. This could be 
done by thin layer chromatography (TLC) followed by a phosphate assay or by high-performance 
liquid chromatography (HPLC) measuring the counts per minute of each peak during elution68,70. 
Alternatively, mass spectrometry is used71. 
Phosphoinositides are not equally distributed within the cell72. Due to their differential 
distribution and because their abundance can change rapidly and transiently upon various 
stimulations (e.g. osmotic shock, growth factor signaling) they are ideal for defining membrane 
identity and participating in signaling events70,73,74. This is, for the most part, done by interactions 
of proteins with the headgroup of one or more phosphoinositides. One example of such effectors 
are the GTPases of the Ras superfamily72. As such phosphoinositides play a role in nearly all 
biological processes and often several phosphoinositide species are involved in these processes. 
Therefore I will give an overview of different cellular processes and the role phosphoinositides 
play in them instead of describing each individual phosphoinositide. 
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1.3.2 PHOSPHOINOSITIDES IN CELLULAR TRAFFICKING PROCESSES 
1.3.2.1 Secretory and Recycling Pathway 
The secretory pathway allows cells to traffic internal components to the outside, either for 
secretion, e.g. neurotransmitters and hormones, or to transport trans-membrane proteins to the 
plasma membrane, e.g. receptors75. This pathway starts at the endoplasmic reticulum. From there 
exocytic cargo is transported to the Golgi apparatus by COP-II vesicles. Secretory cargo is sorted 
within the Golgi apparatus and secretory vesicles are formed and transported to the plasma 
membrane75. Work, mostly done in yeast, shows that PI(4)P plays important roles in this 
process76. It is formed locally at the ER exit sites (ERES) from which the COP-II vesicles 
transport cargo to the Golgi. A study showed that PI(4)P is involved in the formation of soluble 
N-ethylmaleimide-sensitive-factor attachment receptor (SNARE) complexes that mediate the 
membrane fusion with the Golgi77. After the secretory cargo was trafficked through the Golgi, 
exocytic vesicles form at the trans-Golgi network (TGN) and are transported by myosin V to the 
plasma membrane. After budding these vesicles are rich in PI(4)P. Together with the GTPase 
Ypt32 PI(4)P recruits Sec2. Sec2 in turn acts as a guanine nucleotide exchange factor (GEF) for 
the Rab family GTPase Sec476. During the transport exocyst subunits are recruited to the vesicle. 
The Sec15 subunit is recruited by interaction with the Sec2/4 complex. This interaction is 
hindered by PI(4)P and only becomes possible as vesicles gradually lose their PI(4)P content 
while being transported to the plasma membrane. The removal of PI(4)P requires Osh4. Osh4 is 
known to exchange PI(4)P with sterols at ER contact sites with the plasma membrane or Golgi 
apparatus. Therefore it is assumed that Osh4 bridges the exocytic vesicle with the ER membrane, 
exchanging PI(4)P with sterol using a PI(4)P gradient as an energy source. In mammalian cells 
the protein OSBP has a similar function as Osh4 in yeast cells. PI(4)P on the ER membrane is 
then immediately dephosphorylated by Sac1 maintaining the PI(4)P gradient76. Finally, more 
exocyst subunits are recruited and the vesicle is tethered to the plasma membrane. Exocyst 
subunits Sec3 and Exo70 bind to PI(4,5)P2, which is enriched at the plasma membrane
76.  
In line with these observations in the secretory pathway, it was shown that PI(4)P also 
plays an important role in recycling of endosomal cargo to the plasma membrane78. The primary 
phosphoinositide on early endosomes is PI(3)P. Dephosphorylation of PI(3)P by MTM1 and 
subsequent phosphorylation by PI4K2α establishes a PI(4)P enriched domain within the 
endosomal membrane. Interaction of exocyst with PI(4)P as well as PI4K2α allows recycling 
back to the plasma membrane78. The common role for PI(4)P in surface delivery in the 
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biosynthetic pathway as well as during recycling strengthens the role of phosphoinositides in 
given membranes a certain identity, in this case defining a portion of the membrane as exocytic.  
1.3.2.2 Clathrin Mediated Endocytosis 
Clathrin mediated endocytosis (CME) is a process in which cells internalize extracellular 
cargo and transmembrane proteins. CME starts by adapter proteins, such as the AP-2 complex, 
being recruited to the plasma membrane. AP-2 localizes to the plasma membrane by binding to 
PI(4,5)P2 and motifs within the cargo proteins
76. AP-2 then recruits the phosphatidylinositol 4-
phosphate 5-kinase 1γ which further increases the local PI(4,5)P2 levels
79. Next, clathrin forms 
what is called a clathrin coated pit and the phosphatase Synaptojanin is recruited, which results in 
reduced PI(4,5)P2 levels and increased PI(4)P levels
76. PI(4)P, either generated by the 
phosphatase or already present at the plasma membrane, is then used as a substrate by class II 
phosphatidylinositol-3-kinase C2α (PI(3)K C2α) to produce PI(3,4)P2 which is required for the 
late stages of endocytosis, possibly because as it recruits sorting nexin 9 (SNX9), a BAR protein 
that helps to promote constriction of the budding vesicle80. Finally dynamin is recruited in a 
PI(4,5)P2 dependent manner mediating scission of the clathrin coated vesicle
81. Further reduction 
of PI(4,5)P2 leads to uncoating of the vesicles which continue the transport into the endosomal 
system. INPP4A/B phosphatases dephosphorylate PI(3,4)P2 enriching the vesicle in PI(3)P, the 
predominant phosphoinositide on early endosomes82. The importance of phosphoinositides for 
endocytosis was exemplified here by clathrin mediated endocytosis. But other mechanisms of 
uptake of extracellular matter, such as phagocytosis, macropinocytosis and fast endophilin 
mediated endocytosis rely on phosphoinositides as well76. 
CME is an excellent example of how different phosphoinositides become important at 
different stages of a process. It starts with the common phosphoinositide of the plasma 
membrane, PI(4,5)P2, and through the action of several kinases and phosphatases ends with a 
vesicle enriched with the phosphoinositide typical for the endosomal system, PI(3)P. It also 
shows that the changes in phosphoinositide composition are not simple on/off switches but rather 
finely-tuned gradual changes. While Synaptojanin decreases the PI(4,5)P2 relatively early during 
CME, the levels remain high enough to help recruiting dynamin to mediate scission at the end of 
the maturation process. Another noteworthy point is the time scale of these events. The time 
between initiation to removal of the clathrin coated pit from the plasma membrane is less than 
one second83. The involvement of several phosphoinositides that are converted into one another 
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in the course of such a process within a relatively short time span nicely shows why 
phosphoinositides are used as such versatile components in signaling networks.  
1.3.2.3 Endosome Maturation 
Cells contain several different endosomal compartments, membrane bound organelles that 
are used in intracellular trafficking, e.g. endocytosis and recycling or biosynthetic delivery of 
membrane proteins84. After endocytosis cargo ends up in the early endosome characterized by the 
presence of Rab5 and PI(3)P. From there cargo can be recycled or traffic through Rab7 positive 
late endosomes, enriched in PI(3,5)P2, to lysosomes for degradation
84,85. Two models exist how 
cargo changes from early to late endosomes. Either both are stable organelles and cargo is 
trafficked by vesicles from early to late endosomes or early endosomes change their identity to 
late endosomes by replacing Rab5 with Rab7 and increase their PI(3,5)P2 content. While there is 
experimental proof for both models, especially the latter is interesting since it involves 
phosphoinositides86,87. In C. elegans Rab5 on early endosomes is kept active by the GEF Rabex5. 
A complex of SAND-1 and CCZ1 can bind and remove Rabex5 thereby deactivating Rab5. 
Furthermore SAND-1/CCZ1 recruits Rab7 to endosomes and activates it, maybe by supported the 
VPS/HOPS complex which has been linked to Rab7 activation86,88,89. When PI(3)P is removed 
with the PI3K inhibitor Wortmannin, SAND-1 is not recruited, therefore PI(3)P levels seem to 
play an important role in the maturation from early to late endosomes. Change from early to late 
endosomes via Rab conversion has been shown in a mammalian cell line as well, pointing toward 
a general principle of endosome maturation90. A recent publication found that the WDR91 is a 
Rab7 effector that binds to active Rab7 and Beclin1, a component of the PI(3)P producing VPS34 
complex. This inhibits the VPS34 complex, reducing the PI(3)P levels of late endosomes89. 
PI(3)P levels can then be further reduced by MTMR2 dephosphorylation and conversion to 
PI(3,5)P2 by PIKfyve
91. PI(3,5)P2 has been described to be more prominent on late endosomes 
and being important for these organelles85,92,93. Therefore these experiments showed how early 
endosome PI(3)P contributes to late endosome maturation which includes a phosphoinositide 
shift towards PI(3,5)P2. 
1.3.2.4 Autophagy 
Macroautophagy is a process in which different stimuli such as starvation or certain 
cytosolic pathogens induce the formation of double membrane organelles engulfing parts of the 
cytoplasm. This so-called autophagosome is delivered to the lysosomes for the cargo to be 
Introduction 
14 
 
degraded94,95. One of the core components of autophagy is the class III PI3-kinase Vacuolar 
Protein Sorting 34 (VPS34). This enzyme works in two different complexes96. Both share three 
components: the catalytic subunit VPS34, the regulatory subunit VPS15, and Beclin-1. While 
complex II is associated with endosomal PI(3)P, complex I contains Atg14 and is involved in 
autophagy96. This class I complex is recruited to ER-mitochondria contact sites by the ULK 
complex, an inductor of autophagy97. PI(3)P is produced at the initiation site of the isolation 
membrane, which will eventually engulf a part of the cytoplasm, and mediates recruitment of 
effector proteins. One of the effectors is the protein WIPI which in turn recruits the ATG5-
ATG12 complex and ATG16. These proteins promote lipidation and membrane association of 
LC3 which mediates autophagosome formation97. Another PI(3)P effector is the double FYVE-
containing protein 1 (DFCP1) that has an ER-binding site as well as PI(3)P binding FYVE 
domains. This could target it to PI(3)P rich ER domains76,97. 
1.3.3 PHOSPHOINOSITIDES IN EPITHELIAL POLARITY 
One important part of epithelial cell polarity not described above was the role of 
phosphoinositides. In the commonly used model, Madin-Darby canine kidney (MDCK) cells, the 
most obvious role is the definition of the apical and basolateral plasma membrane domains. 
PI(4,5)P2 is found more at the apical plasma membrane while PI(3,4,5)P3 defines the basolateral 
plasma membrane15,20. The domains are kept apart by tight-junctions and localized enzymatic 
activity76. If exogenous PI(3,4,5)P3 is added to the apical site of polarized MDCK monolayers it 
induces the formation of membrane protrusions that have a basolateral characteristic as can be 
seen by the presence basolateral markers such as p58, syntaxin4, sec8 and the absence of the 
apical marker Podocalyxin. Also PI3K, the enzyme making PI(3,4,5)P3 re-localized to these 
protrusions, arguing for a positive feedback loop strengthening the PIP3 signaling. The 
basolateral proteins found in these protrusions were not delivered via the biosynthetic pathway 
but relocalized from the basolateral membrane20. Class I PI3-kinase p110δ was shown to localize 
to the basal membrane and inhibition resulted in impaired polarity98 .This makes it a likely source 
of basolateral PI(3,4,5)P3, most likely after activation through integrin signaling99,100. Similar 
experiments have been done with the apical membrane which is enriched in PI(4,5)P2 and 
exogenous PI(4,5)P2 at the basolateral membrane will induce recruitment of apical proteins to the 
basolateral membrane15. This provides another example of how presence of certain 
phosphoinositides defines membrane identity. In the same way as presence of PI(4)P defines 
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membrane as exocytic (see above), presence of PI(3,4,5)P3 or PI(4,5)P2 define a membrane as 
basolateral or apical and intracellular trafficking is directed accordingly.  
Furthermore, a role for the PI(3,4,5)P3 specific 3-phosphatase PTEN in polarity and 
barrier function has been shown in human colorectal cancer cells Caco-2/15, HCT116, and 
CT26101. PTEN is localized at the border between the apical and basolateral domain by 
interaction with PAR3102. This helps to separate both plasma membrane domains as the 
conversion of PI(3,4,5)P3 to PI(4,5)P2 not only removes the basolateral marker but also 
accumulates the apical marker. shRNA mediated down regulation of PTEN in Caco-2/15 cells 
slowed down polarization, reduced the number of apical microvilli, caused disorganized tight 
junctions and subsequently decreased trans-epithelial electrical resistance (TEER) in Caco-2/15 
cells. Loss of PTEN in HCT116 and CT26 cells was shown increase their metastatic potential 
when they were injected into the tail vein of mice101. 
A recent paper showed the importance of endosomal PI(3)P for epithelial integrity103. 
Loss of the endosomal VPS34 complex, VPS34 complex II, in Drosophila resulted in disrupted 
epithelia as shown by formation of multilayered epithelia, intracellular accumulation of 
adherence junction proteins and overlap of apical and basolateral marker proteins. This could be 
reproduced in the human colon carcinoma cell line Caco-2103. Inhibition or loss of VPS34 
resulted in an increased number of spheroids with multiple lumen. This could be linked to PI(3)P 
which recruits the protein WDFY2 through interaction with its PI(3)P binding FYVE domain. 
Other important roles of PI(3)P have been shown in C. elegans where early endosome dynamics 
are involved in keeping PAR proteins polarized or the already mentioned role of endocytosis in 
regulating Crumbs surface levels34,104. Therefore, one can imagine that the initial integrin 
signaling via PI3K induces the formation of the apico-basal axis in a Rac1-dependent manner and 
by accumulation of the basolateral marker PI(3,4,5)P3. The induced polarity program will lead 
PAR3 to the apical pole where it recruits PTEN that, together with kinases, establishes the 
accumulation of PI(4,5)P2 as a determinant of the apical plasma membrane. Together with the 
numerous phosphoinositides involved in intracellular trafficking, polarity is established and 
maintained72. 
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1.3.4 PHOSPHOINOSITIDES IN IMMUNITY 
Phosphoinositides have also been linked to the immune response. One interesting example is 
TLR4 signaling that can occur either from the plasma membrane or endosomes resulting 
primarily in inflammatory cytokine or interferon production respectively42. It was shown that the 
sorting adaptor TIRAP has a PI(4,5)P2 binding domain required for its plasma membrane 
localization and its subsequent recruitment of the signaling adaptor MyD88105. If the PI(4,5)P2 
binding domain was removed or replaced with a domain binding PI(3)P, PI(4)P, or PI(3,4,5)P3 
LPS signaling was abrogated. Next, TLR4 is taken up by the cell to signal in an TRIF/TRAM 
dependent manner106. It was published that IP3 production by phospholipase Cγ-2 (PLCγ-2) 
cleavage of PI(4,5)P2 as well as PI(3,4,5)P3 production by the class I PI3K p110δ are important in 
TLR4 endocytosis and subsequent TRIF/TRAM signaling107,108. It is tempting to speculate that 
the outcome of TLR4 signaling does not only depend on the receptor’s localization but also on 
membrane phosphoinositide composition. And while the role of phosphoinositides in 
TRAM/TRIF signaling are not yet clear, it has been shown that another adaptor, WD repeat and 
FYVE-domain containing protein 1 (WDFY1, FENS-1), mediates TLR3 and TLR4 signaling by 
recruiting TRIF109. WDFY1 function depends on the presence of its PI(3)P binding FYVE 
domain109,110. Therefore WDFY1 links the endosomal phosphoinositide composition to the 
outcome of TLR4 signaling. The mechanism described above is most likely not complete. When 
TIRAP’s requirement for PI(4,5)P2 was described, it was speculated that loss of PI(4,5)P2 results 
in dissociation of TIRAP/MyD88 which allows TRIF/TRAM to take over. The same group later 
found that TIRAP can actually signal from endosomes111. This was attributed to its ability to bind 
phosphoinositides besides PI(4,5)P2. While a PI(4,5)P2 specific TIRAP would allow TLR4 but 
not TLR9 signaling, a PI(3)P- or phosphatidylserine-specific mutant could be used for TLR9 
signaling111. 
Compartment-specific signaling has also been shown for TLR9 where the outcome, 
proinflammatory cytokines or type I interferon, depends on the endosome112. When TLR9 is in 
VAMP3+ endosomes it induces NF-κB dependent production of proinflammatory cytokines. 
When TLR9 is trafficked into LAMP2+ lysosome-related organelles (LROs), IRF7 mediated 
signaling will result in type I interferons. This AP-3 mediated trafficking depends on the PI(3)P 
5-kinase PIKfyve which as previously been shown to be involved in maturation of CpG 
containing endosomes92. It also fits well with the requirement for AP-3, as it was reported that 
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AP-3 can bind PI(3,5)P2
113. And while PIKfyve inhibitor treatment could not be counteracted by 
addition of exogenous PI(5)P or PI(3,5)P2, this could simply due to the short half-life such lipids 
have20. 
1.4 AIMS OF PHOSPHOINOSITIDE PROJECT 
Over the last decades, our understanding of the importance of phosphoinositides in many 
cellular processes has drastically increased. It was shown that phosphoinositides are involved in 
establishing polarity, either by directly defining the apical and basal pole or by participating in 
polarized trafficking processes. Also a role for phosphoinositides in the innate immune response 
in general as well as in polarized cells has been shown. In our lab, we are interested in immunity 
in the human intestine. Unfortunately most work regarding phosphoinositides and polarity or 
immunity has not been done in intestinal epithelial cells. In most cases either very different 
organisms such as Drosophila and C. elegans or cells from unrelated tissues such as MDCK cells 
are used. Both polarity and immunity are of paramount importance in this system. Only polarized 
IECs can form a tight epithelium that serves as a physical barrier. Also the epithelium is in 
constant contact with a staggering number of microorganisms that have to be tolerated. A 
phenotype in which not only immune regulation plays a role but also the polarized state of cells. 
This tight interplay between polarity and immunity make the intestinal epithelium a highly 
interesting model to investigate both. Therefore the goal of this project is to investigate the role of 
endosomal PI(3)P on intestinal epithelial cell polarity and immunity and establish the tools 
necessary to do so. 
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1.5 INTRODUCTION TO THE BACMAM PROJECT 
1.5.1 BACULOVIRUSES 
Baculoviruses are insect-specific viruses with large (80-180 kb), circular, double stranded 
DNA genomes114. These viruses have long since been used for various applications such as pest 
control or for expression of recombinant proteins in biotechnology115. Among the different 
Baculovirus species, the Autographa californica multiple nucleopolyhedrovirus (AcMNPV) is 
the one most commonly used in biotechnology and normally only infect hosts of the Lepidoptera 
order114. AcMNPV can be engineered to encode mammalian proteins which can then be produced 
by insect cells114,115. Insect cells such as Sf9 can grow in suspension culture, therefore it is 
possible to produce very large quantities of proteins and scale up production. While large scale 
production of recombinant proteins can technically be done in bacteria cells as well, insect cells 
offer the advantage of a eukaryotic system for posttranslational modifications114. While it is not 
exactly the same as the mammalian system, it is still close enough to produce proteins for 
application in humans, e.g. the human papillomavirus vaccine Cervarix (Glaxo-SmithKline)116. 
Additionally they are an advantageous system because of the absence of human pathogens in 
Lepidoptera cell lines and they can grow without serum114. 
With all the advantages of baculoviruses, e.g. large capacity, no replication or integration in 
mammalian cells, low cytotoxicity, easy production of large quantities with high titers, these 
viruses unfortunately were not usable as vectors to transduce mammalian cells as there promoters 
are only active in insect cells117,118. In 1996, this changed when the genome of AcMNPV was 
modified to include a mammalian expression casstte119. Now these viral vectors could be used to 
deliver large cargo into mammalian cells and have been used for a variety of applications. 
Examples include the expression of shRNAs, tagging HMGA1 by inserting GFP its locus in 293T 
cells by simultaneously encoding the GFP homology construct, Cas9 and two guide RNAs, and 
reprogramming MEFs into a neuronal phenotype by using one Baculovirus expressing three 
factors instead of three lentiviral vectors120,121. 
While this system offers many advantages and has been used for numerous different 
applications, some uses are hindered because the viral genome remains episomal and expression 
is lost within two to three weeks (Figure 24 B)122. To achieve long lasting expression several 
different methods were tested. Expression of the Epstein-Barr virus protein EBNA1 and inclusion 
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of the oriP sequence extended the expression for 35 days123. A second method used adeno-
associated virus (AAV) inverted terminal repeats (ITRs) and the AAV rep gene in human 
embryonic stem cells which allowed for the mechanical selection of GFP positive cells during 
passaging123,124. A third method is through integration using the sleeping beauty (SB) transposon. 
This method was successfully used to achieve prolonged shRNA expression in HEK 293T cells 
and synoviocytes, GFP expression in HepG2 cells and murine eyes in vivo, and GFP expression 
in HEK293T cells120,122,123.  
1.5.2 SCAFFOLD / MATRIX ATTACHMENT REGION 
While the above mentioned methods to prolong maintenance of expression do work, they 
do raise questions about the biosafety. Normal baculovirus vectors can be handled under S1 
biosafety conditions. The vectors described above either rely on integration into the host cell 
genome (SB transposon or AAV ITRs) or require the expression of a viral gene, EBNA1, that has 
been associated with the development of B cell neoplasia in mice and induction of epithelial-to 
mesenchymal transition (EMT) in nasopharyngeal cancer cells, a process linked to 
metastasis125,126. Therefore we decided to try another method of creating a persistent BacMam 
vector utilizing a scaffold / matrix attachment region (S/MAR). S/MAR regions were first 
described in 1984 as being involved in organization of chromatin loops127. Numerous functions 
have been assigned to these sequences. It is believed that by interacting with the nuclear matrix, 
they form loop structures in which active transcription can take place and where they insulate the 
gene from negative regulators of transcription on the surrounding chromatin128. The S/MAR 
regions have been described as regulating gene expression and enhancing expression. In 1999 it 
was published that vectors in which the gene encoding the SV40 large T-antigen was replaced 
with the S/MAR region from the human interferon β gene are stably maintained in CHO cells at 
low copy numbers without integration, something that since has been shown for other cell lines 
as well129–132. Such vectors can also be used for in-vivo applications. When naked plasmid DNA 
containing S/MAR sequences were injected into mice or rats it resulted in transgene expression 
for several months133,134. As it was shown that S/MAR regions that do not belong to a gene are 
not anchored to the matrix, active transcription is required for the S/MAR region to work128. This 
was further verified by comparing integration and episomal maintenance of vectors expressing 
GFP followed by the S/MAR sequence with plasmids lacking the promoter or having the 
polyadenylation site between GFP and S/MAR. Only vectors in which active transcription that 
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included the S/MAR region took place were episomally maintained135. The S/MAR region can 
then interact with the nuclear matrix protein SAF-A which explains how the plasmid is 
anchored136. It was shown that typical proteins of the pre-replication complexes are found on 
episomal S/MAR plasmids which are replicated once per cell cycle early in the S-Phase137. 
Establishment of anchored plasmids that are stably maintained is not an efficient process though, 
only 1-5% of transfected CHO cells were able to stably maintain an S/MAR plasmid. But once it 
is established the plasmid is maintained without selection pressure138. Also the S/MAR region 
seems to prevent integration of the plasmid as a vector with S/MAR is maintained episomally in 
CHO or HeLa cells while the same vector without S/MAR integrates129,137. S/MAR also 
positively influences the transgene’s expression. It was shown that S/MAR containing episomes 
are found in nuclear compartments associated with active transcription and that the CMV 
promoter on S/MAR episomes is not epigenetically silenced by cytosine methylation while the 
same plasmid linearized, so that the S/MAR region is removed, integrates into the genome and 
the CMV promoter is methylated138,139. 
1.6 AIMS OF BACMAM PROJECT 
We want to improve the BacMam system already established in our lab by adding an S/MAR 
sequence, combining the advantages of both systems: the easily produced viral vector with large 
cargo capacity and a DNA sequence allowing plasmids to be episomally maintained for months. 
Such a vector can be a tremendous asset for the lab. To modify our model cell line, T84 cells, we 
have to stably transduce them with lentiviral vectors. BacMam could provide a safer alternative 
usable in biosafety level 1 environments. Also some constructs used in our lab are close the 
maximum cargo capacity of lentiviral vectors and if cells have to express several transgenes, we 
have to go through several rounds of transduction and selection. Making T84 cell lines takes a 
long time as cells have to be transduced after being seeded very sparse and they grow very slow. 
Having a vector that can express multiple proteins at the same time would save time due to a 
single round of transduction. Also such a vector can be modified to deliver large reporters of the 
immune response which can be interesting for the lab and the immunity part of the 
phosphoinositide project. 
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2 MATERIALS AND METHODS  
2.1 MATERIALS 
2.1.1 BACTERIA AND MAMMALIAN CELLS 
Table 1: List of bacteria.
 Name Reference Description 
DH5α Invitrogen 
18265017 
Subcloning efficiency bacteria used in routine 
cloning. 
NEB® 5-alpha 
Competent E. coli 
(High Efficiency) 
New England Biolabs 
C2987H 
Part of NEBuilder Hifi Assembly kit, in some cases 
also used as an alternative to normal DH5α if higher 
efficiency was necessary. 
DH10Bac Invitrogen 
10361012 
MAX Efficiency® DH10BacTM Competent Cells 
used to produce recombinant bacmids. 
ccdB Survival™ 2 Invitrogen 
A10460 
Cells resistant to the ccdB kill gene used in 
Gateway cloning. Used to propagate empty 
Gateway entry- or destination plasmids. 
 
Table 2: List of eukaryotic cells. 
Name Reference Description 
T84 ATCC 
ATTC-CCL-248 
Human colon carcinoma cell line. Maintained in collagen 
(from rat tail) coated flasks in DMEM/F12 with 10% FBS, 
100 U/ml penicillin, and 100µg/ml streptomycin.  
HEK-293T ATCC 
ATCC CRL-3216 
Human embryonic kidney cell line used to produce 
lentiviral vectors and for standard transfection / 
transduction tests. Maintained in IMDM with 10% FBS, 
100 U/ml penicillin, and 100µg/ml streptomycin. 
HeLa Kyoto Gift from Department of 
Infectious Diseases, 
Virology, University 
Hospital Heidelberg 
Human cervical cancer cell line that is easy to transfect 
and is routinely used as a model system to test outcome of 
changes in PIP levels introduced by the chemical 
dimerization system. Maintained in DMEM with 10% 
FBS, 100 U/ml penicillin, and 100µg/ml streptomycin. 
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A549 Gift from Department of 
Infectious Diseases, 
Molecular Virology, 
University Hospital 
Heidelberg 
Human lung epithelial cells. Maintained in DMEM with 
10% FBS, 100 U/ml penicillin, and 100µg/ml 
streptomycin. 
L929 Terence S. Dermody, 
Department of Pediatrics 
at the University of 
Pittsburgh School of 
Medicine 
Murine fibroblast cell line. After thawing grown as 
adherent culture in DMEM with 10% FBS, 100 U/ml 
penicillin, and 100µg/ml streptomycin at 37 °C with 5% 
CO2. Then transferred to suspension culture in MEM 
Eagle (Joklik Modification) with 2 g/L NaHCO3, 2 mM L-
Glutamine, 5% (v/v) FBS, 5% (v/v) newborn calf serum. 
Suspension cultures are grown at 35 °C without CO2 in 
spinner flasks at 140 rpm. 
Sf9  
(SFM adapted) 
Gibco 
11496-015 
Insect cell line (from Spodoptera frugiperda) maintained 
in suspension culture in SF-900 III SFM (1x) medium 
without serum or antibiotics. Cells were grown at 27 °C 
without CO2 at 110 rpm. 
 
2.1.2 CELL CULTURE MEDIA AND SUPPLEMENTS 
Table 3: List of cell culture media and supplements. 
Name Reference 
DMEM/F12 Gibco 
31330-038 
DMEM Gibco 
41965-039 
IMDM Gibco 
21980-032 
F12 Ham Gibco 
21765-029 
MEM Eagle (Joklik Modification) Sigma, 
M0518-10X1L 
OptiMEM I Reduced Serum Medium Gibco 
31985-062 
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Sf-900 III SFM (1x) Gibco 
12658-019 
Grace’s Insect Medium (unsupplemented) Gibco 
11595-030 
FBS Biochrom GmbH 
S 0615 
NBCS Gibco 
26010-074 
Pen/Strep (10,000 U/ml penicillin + 10,000 µg/ml 
Streptomycin) 
Gibco 
15140-122 
0.05% Trypsin-EDTA Gibco 
25300-054 
0.25% Trypsin-EDTA Gibco 
25200-056 
Puromycin dihydrochloride Sigma-Aldrich 
P9620-10ml 
Geneticin (G418 Sulfate) Gibco 
10131027 
Blasticidin S HCl Gibco 
R210-01 
 
2.1.3 ANTIBODIES 
Table 4: Primary antibodies. 
Antibody Reference Raised in Dilution IF Dilution Western 
blot 
α-beta-actin  Sigma-Aldrich 
A5441 
Mouse - 1:5,000 
α-VPS34 
(D9A5) 
Cell Signaling 
#4263 
Rabbit - 1:1,000 
α-MTM1 Volker Haucke, 
Leibniz Institut für 
Molekulare Pharmakologie 
Rabbit - 1:250 
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α-GFP Abcam 
ab6556 
Rabbit 1:500 - 
α-µNS Steeve Boulant Guinea Pig 1:5,000 1:5,000 
α-PI(3)P Echelon Biosciences Inc. 
Z-P003 
Mouse 1:200 - 
 
Table 5: Secondary antibodies. 
Antibody Reference Raised in Dilution IF Dilution Western 
blot 
α-rabbit-IgG HRP GE Healthcare 
NA934 
Donkey - 1:5,000 
α-mouse-IgG HRP GE Healthcare 
NA931 
Sheep - 1:5,000 
α-mouse IgG-488 Molecular Probes 
A11001 
Goat 1:1,000 - 
α-mouse IgG-568 Molecular Probes 
A11004 
Goat 1:1,000 - 
α-mouse IgG-647 Molecular Probes 
A21235 
Goat 1:1,000 - 
α-rabbit IgG-488 Molecular Probes 
A11008 
Goat 1:1,000 - 
α-rabbit IgG-568 Molecular Probes 
A11011 
Goat 1:1,000 - 
α-rabbit IgG-647 Molecular Probes 
A21244 
Goat 1:1,000 - 
α-mouse-IgG- 
IRDye 680RD 
LI-COR 
925-68070 
Goat 1:10,000 – 
1:20,000 
- 
α-mouse-IgG- 
IRDye 800CW 
LI-COR 
926-32210 
Goat 1:10,000 – 
1:20,000 
- 
α-guinea pig-IgG- 
IRDye 800CW 
LI-COR 
925-32411 
Donkey 1:10,000 – 
1:20,000 
- 
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2.1.4 OLIGONUCLEOTIDES 
Table 6: shRNA oligonucleotides.  Targeting sequence is underlined.
Name Sequence (5’ to 3’) 
shMTM1 #1 fwd CCGGGCATTGAAGGGTTCGAAATACCTCGAGGTATTTCGAACCCTTC
AATGCTTTTTG 
shMTM1 #1 rev AATTCAAAAAGCATTGAAGGGTTCGAAATACCTCGAGGTATTTCGA
ACCCTTCAATGC 
shMTM1 #2 fwd CCGGGATGCAAGACCCAGCGTAACTCGAGTTACGCTGGGTCTTGCA
TCTTTTTG 
shMTM1 #2 rev AATTCAAAAAGATGCAAGACCCAGCGTAACTCGAGTTACGCTGGGT
CTTGCATC 
shScrambled for CCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATC
TTGTTGTTTTTG 
shScrambled rev AATTCAAAAACAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTC
TTCATCTTGTTG 
shVPS34 #1 for CCGGGAGGCAAATATCCAGTTATATCTCGAGATATAACTGGATATTT
GCCTCTTTTTG 
shVPS34 #1 rev AATTCAAAAAGAGGCAAATATCCAGTTATATCTCGAGATATAACTG
GATATTTGCCTC 
shVPS34 #2 for CCGGCCACGAGAGATCAGTTAAATACTCGAGTATTTAACTGATCTCT
CGTGGTTTTTG 
shVPS34 #2 rev AATTCAAAAACCACGAGAGATCAGTTAAATACTCGAGTATTTAACT
GATCTCTCGTGG 
shVPS34 #3 for CCGGCCCATGAGATGTACTTGAACGTAATCTCGAGATTACGTTCAA
GTACATCTCATGGGTTTTTG 
shVPS34 #3 rev AATTCAAAAACCCATGAGATGTACTTGAACGTAATCTCGAGATTAC
GTTCAAGTACATCTCATGGG 
 
Table 7: Sequencing primers. 
Name Sequence (5’ to 3’) 
Blasticidin-rev GCTCTTTCAATGAGGGTGGA 
ccdB-F CACCGCGAAAATGAC 
M13-FP TGTAAAACGACGGCCAGT 
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M13-RP CAGGAAACAGCTATGACC 
Puro-F GAGGTGCCCGAAGG 
Puro-R GTTCTTGCAGCTCGG 
U6 AGATATTAGTACAAAATACG 
Gent-F TACAAAGTTGGGCATACG 
Gent-R CGTAACATCGTTGCTGC 
Polyhedrin-F CTTATTTATTTGCGAGATGG 
Polyhedrin-R ATTCCGGATTATTCATACC 
Amp-F GGCAACTATGGATGAACG 
Amp-R TTTCACCAGCGTTTCTG 
pBR322-F GCAAGCAGCAGATTACG 
pBR322-R TGTGATGCTCGTCAGG 
 
Table 8: qRT-PCR primers. 
Name Efficiency (%) Sequence (5’ to 3’) 
HPRT1-fwd 102 CCTGGCGTCGTGATTAGTGAT 
HPRT1-rev  AGACGTTCAGTCCTGTCCATAA 
IFNβ1-fwd 110.7 GCCGCATTGACCATCTAT 
IFNβ1-rev  GTCTCATTCCAGCCAGTG 
IFNλ-fwd 110.6 GCCACATAGCCCAGTTCAAG 
IFNλ-rev  TGGGAGAGGATATGGTGCAG 
IL-8-fwd 98.7 GAGAGTGATTGAGAGTGGACCAC 
IL-8-rev  CACAACCCTCTGCACCCAGTTT 
β-actin-fwd 99.3 CATGTACGTTGCTATCCAGGC 
β-actin-rev  CTCCTTAATGTCACGCACGAT 
 
Table 9: Cloning primers. 
Name Sequence (5’ to 3’) Description 
hMTM1-
C375S-F 
CAGTGCTTGTGCATTCCAGTGACGGATGGG Primers for site directed 
mutagenesis inducing 
phosphatase-dead mutation in 
hMTM1. 
hMTM1-
C375S-R 
CCCATCCGTCACTGGAATGCACAAGCACTG 
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pCMV-
DEST-R 
TACCACTTTGTACAAGAAAGC Primers to amplify the BacMam 
pCMV-DEST backbone to insert 
PuroR-S/SMAR with NEBuilder 
HiFi Assembly.  
pCMV-
DEST-F 
AATCAGCCATACCACATTTG 
P2A-puro-
SMAR-F 
CTTTCTTGTACAAAGTGGTATCTGGCAGCGG
CGCCACC 
Primers to amplify the P2A-puro-
S/MAR sequence from pMAX-
SMAR-GFP-P2A-Puro to create a 
BacMam backbone with 
puromycin resistance. 
P2A-puro-
SMAR-R 
CAAATGTGGTATGGCTGATTACCGTCGACTG
CAGAATTCTATCAAATATTTAAAGAAAAAAA
AATTG 
 
2.1.5 PLASMIDS 
Table 10: Plasmids used or created in this thesis.
Name Description 
BacMam  pCMV-Dest Gateway destination vector for Baculovirus production. Can be 
transformed into DH10Bac to create recombinant bacmids via 
transposition. 
Source: Invitrogen, A24223 
pWPI-puro-rfB Lentiviral Gateway destination plasmid expressing puromycin resistance 
gene from an IRES. 
Source: University of Heidelberg Department of Infectious Diseases 
Molecular Virology 
pWPI-neo-rfB Lentiviral Gateway destination plasmid expressing neomycin resistance 
gene from an IRES. 
Source: University of Heidelberg Department of Infectious Diseases 
Molecular Virology 
pWPI-blr-rfB Lentiviral Gateway destination plasmid expressing blasticidin resistance 
gene from an IRES. 
Source: University of Heidelberg Department of Infectious Diseases 
Molecular Virology 
pLKO.1 Lentiviral expression plasmid for shRNAs using a U6 promoter. shRNAs 
are cloned via AgeI and EcoRI restriction sites. Can be selected with 
puromycin. 
Source: The RNAi Consortium140 
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pMD.2G Second generation lentiviral envelope plasmid expressing VSV-G. 
Source: pMD2.G was a gift from Didier Trono (Addgene plasmid # 
12259) 
psPAX2 Second generation lentiviral helper plasmid. 
Source: psPAX2 was a gift from Didier Trono (Addgene plasmid # 
12260) 
pDONR221 Gateway donor plasmid with kanamycin resistance. Used to create entry 
clones. 
Source: Invitrogen, 12535-019 
BacMam pCMV-DEST-puro-
SMAR 
Gateway destination vector for production of recombinant bacmids. 
Based on BacMam pCMV-Dest with addition of puromycin resistance 
gene and S/MAR region allowing episomal maintenance. 
BacMam pCMV-DEST-neo-
SMAR 
Gateway destination vector for production of recombinant bacmids. 
Based on BacMam pCMV-Dest with addition of geneticin resistance 
gene and S/MAR region allowing episomal maintenance. 
BacMam pCMV-DEST-blr-
SMAR 
Gateway destination vector for production of recombinant bacmids. 
Based on BacMam pCMV-Dest with addition of blasticidin resistance 
gene and S/MAR region allowing episomal maintenance. 
pMAX-SMAR-GFP-P2A-
Puro 
Plasmid expressing coGFP followed by a ‘self-cleaving’ P2A sequence 
from porcine teschovirus-1 polyprotein and the puromycin resistance 
gene. S/MAR sequence allows episomal maintenance. 
Source: Richard Harbottle, German Cancer Research Centre (DKFZ)  
pmCherry-C1 Used to amplify mCherry to construct pCMV-mCherry-puro-reporter. 
Source: Clontech, 632524 
BacMam  pCMV-mCherry-
puro-reporter 
Gateway destination vector for production of recombinant bacmids. 
Based on BacMam pCMV-DEST-puro-SMAR. The gateway cloning 
cassette was replaced with constitutively expressed mCherry. A new 
Gateway cloning cassette was to insert to allow cloning of a promoter 
with reporter gene. 
pWPI-Puro-FRB*-GFP-Rab5 Lentiviral expression plasmid with the GFP-tagged Rab5 anchor for the 
chemical dimerization system. 
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pWPI-Puro-FRB*-CFP-Rab5 Identical to pWPI-Puro-FRB*-GFP-Rab5 except CFP is used as a 
fluorescent marker. 
pWPI-Blr-mRFP-FKBP-
hMTM1 
Lentiviral expression plasmid with the mRFP-tagged recruitable MTM1 
wildtype enzyme for the chemical dimerization system. 
pWPI-Blr-mRFP-FKBP-
hMTM1-C375S 
Lentiviral expression plasmid with the mRFP-tagged recruitable MTM1 
C375S mutant enzyme for the chemical dimerization system. 
pWPI-Blr-GFP-2xFYVE Lentiviral expression plasmid for GFP-coupled tandem FYVE domains 
from Hrs. Used as a PI(3)P sensor. 
 
2.1.6 CHEMICALS AND ENZYMES 
Table 11: List of chemicals. 
1 kb Plus DNA Ladder Invitrogen, 10787-018 
2-butanol Roth, KK02.2 
2-propanol Roth, T910.1 
30% Acrylamide/Bis-acrylamide solution (37.5:1) Roth, 3029.1 
Agarose Roth, 3810.2 
Albumin standard Thermo Scientific, 23210 
Ammonium chloride Sigma, A9434 
Ampicillin (sodium salt) Roth, K029.2 
APS Roth, 9592.2 
Boric acid Roth, 6943.1 
Bromophenol blue AppliChem, A2331,0005 
BSA New England Biolabs, B9001S 
Cesium chloride Sigma-Aldrich, C3139 
CFC-113 (1,1,2-Trichloro-1,2,2-trifluoroethane) Sigma-Aldrich, 34874 
Collagen (from rat tail) Sigma-Aldrich, C7661 
Complete protease inhibitor cocktail EDTA-free Roche, 04693159001 
CutSmart buffer New England Biolabs, B7204S 
D-(+)-Glucose Sigma-Aldrich, G5767 
DAPI Sigma, D9542 
DC Protein Assay Kit II Bio-Rad, 5000112 
Deoxycholate (sodium salt) Sigma-Aldrich, D6750 
ECL Western Blotting Reagents GE Healthcare, RPN2106 
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EDTA (disodium salt dihydrate) Sigma, E5134 
ELISA kit: DIY Human IFN Lambda 2/3 (IL-28A/B) pbl assay science, 61830 
ELISA kit: Human IL-6 ELISA MAX Standard Set BioLegend, 430502 
ELISA kit: Human IL-8 ELISA MAX Standard Set BioLegend, 431502 
Ethanol Sigma-Aldrich, 32205 
Ethidium bromide MPBio, ETBC1001 
Gateway® BP Clonase II Enzyme mix Invitrogen, 11789020 
Gateway® LR Clonase® II Enzyme mix Invitrogen, 11791020 
GFP-FYVE (Hrs), purified protein Gift from Volker Haucke, FMP Berlin 
Glycerol Roth, 7530.1 
Glycine Gerbu , #1023 
HBSS (with calcium, with magnesium, without phenol red) Sigma, 55037C-1000ML 
IPTG Sigma-Aldrich, I6758 
iScript cDNA Synthesis Kit Bio-Rad, 170-8891 
LB Roth, X968.2 
LB-Agar Roth, X969.2 
L-Glutamic acid Sigma, G1251 
Lipofectamine 2000 Invitrogen, 11668-019 
Methanol Sigma-Aldrich, 32213 
NEBuilder HiFi DNA Assembly Cloning Kit New England Biolabs, E5520S 
Nonfat dried milk powder AppliChem, A0830 
Odyssey® Blocking Buffer (TBS) Li-Cor, 927-50000 
pH-indicator stripes, pH 5.0 – 10.0 Merck, 1.09533.0001 
Phosphate buffered saline (PBS) Sigma, P4417 
PhosphoSTOP phosphatase inhibitor cocktail Roche, 04906837001 
Phusion Hot Start II DNA Polymerase Thermo Scientific, F549S 
Poly(I:C) high molecular weight (HMW) Invivogen, tlrl-pic 
Poly(I:C) low molecular weight (LMW) Invivogen, tlrl-picw 
Polybrene (Hexadimethrine bromide) Sigma-Aldrich, 107689-10G 
Polyethylenimine, branched (PEI) Sigma-Aldrich, 408727 
Potassium acetate Roth, HN10.3 
Precision Plus Protein Dual Color Bio-Rad, 1610374 
ProLong Gold Antifade Mountant with DAPI Molecular Probes, P36935 
ProLong Gold Antifade Mountant with DAPI Molecular Probes, P36934 
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Rapalog (A/C Heterodimerizer, AP21967) TaKaRa, 635057 
Restriction enzymes New England Biosciences 
RNase A Qiagen, 19101 
SAR405 BioVision, B1286-5,25 
Slide-A-Lyzer Dialysis Cassette, 20,000 MWCO Thermo Scientific, 66003 
SOB medium powder Roth, AE27.1 
Sodium bicarbonate (NaHCO3) Sigma, S5761 
Sodium chloride Roth, HN00.2 
Sodium deoxycholate Sigma-Aldrich, D6750 
Sodium dodecyl sulfate (SDS) Roth, 2326.2 
Sodium hydroxide Roth, 9356.1 
Stready-Glo Luciferase Assay System Promega, E2510 
SuperSignal West Femto Chemiluminescent Substrate  Thermo Scientific, 34095 
T4 DNA ligase New England Biolabs, M0202 
TEMED Roth, 2367.1 
Tetracycline hydrochloride Sigma-Aldrich, T7660-5G 
Tris base Roth, 5429.3 
Triton X-100 G-Biosciences, 786-513 
TurboFect Thermo Scientific, R0531 
Tween 20 MP Biomedicals, TWEEN201 
VPS34-IN1 Cayman Chemical, 17392 
WesternBright Chemiluminiszenz Substrat Sirius Biozym, 541021 
X-Gal Sigma-Aldrich, B4252 
β- mercaptoethanol / 2-mercaptoethanol Sigma-Aldrich, M6250 
 
2.1.7 BUFFERS AND SOLUTIONS 
0.5x TBE  
Tris base 50 mM 
Boric acid 50 mM 
EDTA 1 mM 
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Blocking solution (western blot)  
Nonfat dried milk powder 5% (w/v) 
(Tris buffered saline with Tween) TBS-T 1x 
 
Blotting buffer  
Tris base 25 mM 
Glycine 190 mM 
 
Laemmli buffer (4x)  
Tris base, pH 6.8 200 mM 
SDS 8% 
Glycerol 40% (v/v) 
β- mercaptoethanol 4% (v/v) 
EDTA, pH 8 50 mM 
Bromophenol blue 0.08% (w/v) 
 
Resuspension buffer  
Tris base, pH 7.5 50 mM 
EDTA 10 mM 
RNase A 100 µg/mL 
 
Lysis buffer  
Sodium hydroxide 0.2 M 
SDS 1% (w/v) 
 
Neutralization buffer  
Potassium acetate, pH 4.8 1.32 M 
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TBS-T (pH 7.6)  
Tris base 20 mM 
Sodium chloride 137 mM 
Tween 20 0.1% (v/v) 
 
RIPA buffer  
Sodium chloride 150 mM 
Triton X-100 1% (v/v) 
Sodium deoxycholate 0.5% (w/v) 
SDS 0.1% (w/v) 
Tris base, pH 8.0 50 mM 
PhosphoSTOP phosphatase inhibitor cocktail 1 tablet per 10 mL 
Complete protease inhibitor cocktail 1 tablet per 10 mL 
 
SDS-PAA running gel buffer (4x)  
Tris base, pH 8.8 1.5 M 
SDS 0.4% (w/v) 
 
SDS-PAA stacking gel buffer (4x)  
Tris base, pH 8.8 0.5 M 
SDS 0.4% (w/v) 
 
SDS-PAGE running buffer  
Tris-base 25 mM 
Glycine 190 mM 
SDS 0.1% (w/v) 
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SDS-PAGE running gel (two 1.5 mm thick gels) 12% 10% 
Acrylamide/Bis-acrylamide solution (30%) 7.2 mL 6 mL 
Water 6.3 mL 7.5 mL 
Running gel buffer 4.5 mL 4.5 mL 
APS (10% w/v) 150 µL 150 µL 
TEMED 30 µL 30 µL 
 
SDS-PAGE stacking gel (two 1.5 mm thick gels) 5% 
Acrylamide/Bis-acrylamide solution (30%) 1 mL 
Water 3.5 mL 
Stacking gel buffer 1.5 mL 
APS (10% w/v) 50 µL 
TEMED 10 µL 
 
SOC medium  
SOB-medium powder 2.66% (w/v) 
D-(+)-Glucose 20 mM 
TBS (pH 7.6)  
Tris base 20 mM 
Sodium chloride 137 mM 
 
Virus buffer  
Sodium chloride 150 mM 
Tris base, pH 7.4 10 mM 
Magnesium chloride 10 mM 
 
Bacmid isolation solution I (filter-sterilize; store at 4 °C) 
Tris-HCl 15 mM 
EDTA pH 8 10 mM 
RNase A 100 µg/ml 
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Bacmid isolation solution II (filter-sterilize) 
NaOH 0.2 N 
SDS 1% (w/v) 
 
DNA loading dye (6x) 
Glycerol 60% (v/v) 
Tris pH 7.5 10 mM 
EDTA pH8 60 mM 
Bromphenol blue 0.03% (w/v) 
 
LB- ampicillin 
LB powder (Roth, X968.2) 25g 
H2O 1 L 
Ampicillin (100 mg/ml) 1 ml 
 
LB-agar-ampicillin 
LB agar powder (Roth, X969.2) 10 g 
H2O 250 ml 
Ampicillin (100 mg/ml) 250 µl 
Add ampicillin when LB-agar cooled down and pour plates of 25 ml each. 
 
LB-kanamycin 
LB powder (Roth, X968.2) 25g 
H2O 1 L 
Kanamycin (50 mg/ml) 1 ml 
 
 
 
 
Materials and Methods 
36 
 
LB-agar-kanamycin 
LB agar powder (Roth, X969.2) 10 g 
H2O 250 ml 
Kanamycin (50 mg/ml) 250 µl 
Add ampicillin when LB-agar cooled down and pour plates of 25 ml each. 
 
LB for DH10Bac selection 
LB powder (Roth, X968.2) 25g 
H2O 1 L 
Kanamycin (50 mg/ml) 1 ml 
Gentamycin (50 mg/ml) 140 µl 
Tetracycline (10 mg/ml) 1 ml 
 
LB-agar plates for DH10Bac selection 
LB powder (Roth, X969.2) 10g 
H2O 250 ml 
Kanamycin (50 mg/ml) 250 µl 
Gentamycin (50 mg/ml) 35 µl 
Tetracycline (10 mg/ml) 250 µl 
X-Gal (100 mg/ml) 200 µl 
IPTG (238 mg/ml) 42 µl 
Add all chemicals when LB-agar cooled down and pour plates of 25 ml each. 
 
HO buffer  
Tris base, pH 7.4 10 mM 
NaCl 250 mM 
2-mercaptoethanol 10 mM 
Filter sterilize (0.2 µM membrane) and stored at 4 °C 
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Dialysis buffer  
Tris base, pH 7.4 10 mM 
NaCl 150 mM 
MgCl2 20 mM 
 
Stripping buffer  
HCl 0.1 M 
2-mercaptoethanol 0.1 M 
Buffer A  
Pipes, pH 6.8 20 mM 
NaCl 137 mM 
KCl 2.7 mM 
 
TE  
Tris-HCl, pH 8 10 mM 
EDTA, pH 8 1 mM 
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2.2 METHODS 
2.2.1 DNA ISOLATION 
Plasmid DNA after cloning was extracted without the use of a commercial kit. All steps 
are carried out at room temperature. Bacteria were pelleted at 11,000 rcf for 1 minute and the 
pellet resuspended in 200 µl resuspension buffer. After addition of 200 µl lysis buffer samples 
were incubated for 3 minutes before 200 µl neutralization buffer was added. Samples were 
centrifuged 10 minutes at 11,000 rcf and the supernatant transferred into a new tube containing 
600 µl 2-propanol. After thoroughly mixing samples they were centrifuged for 10 minutes at 
11,000 rcf. Supernatant was removed and pellets washed with 300 µl 70% EtOH (v/v), 
centrifuged at 11,000 rcf for 5 minutes and pellets dried before resuspension in 30 µl H2O or TE 
buffer. Other plasmid preparations were done using commercial kits according to the 
manufacturer’s instructions. Macherey-Nagel NucleoSpin® Plasmid (740588.250) for small scale 
purifications of 1-2 ml, Macherey-Nagel NucleoBond® PC 100 (740573.100) for 20-100 ml and 
Qiagen Plasmid Maxi prep (12163) for 100-200 ml of bacterial culture. 
2.2.2 DNA PURIFICATION 
Gel extraction of DNA bands and purification of PCR reactions and restriction digests 
were done with the Macherey-Nagel NucleoSpin® Gel and PCR Clean-up kit (740609.250) 
according to manufacturer’s instructions. Volume of elution buffer was between 20 and 40 µl 
(depending on amount of input DNA). 
2.2.3 AGAROSE GEL ELECTROPHORESIS 
Agarose was dissolved in 0.5% TBE. 0.8% (w/v) agarose was used except for quality 
control of qRT-PCR primers for which a 2% (w/v) gel was used to verify single bands. Gels were 
cast with the Bio-Rad Mini-Sub Cell GT Cell or Sub-Cell GT Cell system and samples mixed 
with 6x DNA loading dye and run at 120V until sufficient separation was reached.  
2.2.4 GATEWAY CLONING 
Gateway cloning was done according to Gateway Technology user guide and the manuals 
of the BP Clonase II mix and the LR Clonase II mix with minor changes. To clone the gene of 
interest (GOI) into pDONR221, the GOI was amplified with Phusion Hot Start II DNA 
polymerase. The PCR conditions were adjusted for every GOI according to the manufacturer’s 
instructions. Primers included recombination sites for the BP clonase (Table 12). PCR reactions 
were run on an agarose gel and the band of the correct size extracted. The purified amplicon was 
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used in a standard 10 µl BP reaction with 50 – 150 ng final amount of amplicon. The reaction 
was left at room temperature over night. After a 10 minute Proteinase K digest, subcloning 
efficiency DH5α were transformed according to the manufacturer’s instructions using the 
complete BP reaction. Individual clones were sent for sequencing. 
For LR reactions 150 ng of entry clone and the desired destination vector each were used 
in a 10 µl reaction for one hour at room temperature. After the 10 minute Proteinase K digest the 
complete reaction was transformed into Subcloning Competent DH5α.  
Table 12: attB primer design guidelines for Gateway Cloning. 
 5’ end attB site Kozak sequence Template specific 
Forward GGGG ACA-AGT-TTG-TAC-AAA-AAA-
GCA-GGC-TTC 
ACC-ATG NNN… 
Reverse GGGG AC-CAC-TTT-GTA-CAA-GAA-AGC-
TGG-GTC- 
 NNN… 
 
2.2.5 NEBUILDER HIFI ASSEMBLY CLONING 
NEBuilder cloning was done using PCR fragments. Primers were designed using the 
NEBuilder Assembly Tool adjusting the settings to Phusion Hot Start polymerase and 2-3 
fragment cloning141. PCR reactions were digested with DpnI (30 minutes 37°C, 20 minutes 80°C) 
to prevent possible carryover of template DNA during the gel purification. 100 ng backbone 
amplicon were mixed with the insert in a 1:3 molar ratio for a 20 µl reaction. The sample was 
incubated at 50°C for one hour and the complete reaction transformed into DH5α or ccdB 
Survival™ 2 in the case of Gateway destination vectors carrying the ccdB kill gene. 
2.2.6 RNA ISOLATION AND QRT-PCR ANALYSIS 
RNA was extracted using the Macherey-Nagel NucleoSpin® RNA kit (740955.250) 
according to manufacturer’s instructions. Samples were eluted in 40 – 60 µl nuclease free water 
and concentration measured using a NanoDrop Lite device (Thermo Scientific). cDNA was 
prepared with Bio-Rad iScript according to the manufacturer’s instructions using 250 ng total 
RNA in a 20 µl reaction. cDNA was diluted 1:1 with water and used for qRT-PCR analysis. qRT-
PCR analysis was done using Bio-Rad iTaq enzyme according to the manufacturer’s instructions 
using a 15µl reaction with 250 nM of each primer and 2 µl diluted cDNA. Samples run on a Bio-
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Rad CFX96 Touch. Analysis was done with the Bio-Rad CFX Manager 3.0.1224.1015 using 
HPRT1 and / or β-actin for normalization and a ΔΔCq analysis. 
2.2.7 PROTEIN EXTRACTION AND CONCENTRATION DETERMINATION 
Cells were washed with PBS to remove FBS prior to lysis. Then cells were lysed by 
addition of RIPA buffer to the well of the cell culture plate. After 5 minutes at room temperature 
the lysate was transferred into a 1.5 ml microcentrifuge tube, spun down at 11,000 rcf for 5 
minutes to pellet cell debris. The supernatant was transferred into a new tube for storage at -80°C. 
Protein concentration was determined using the BioRad DC Protein Assay Kit with the 
microplate protocol. 5 µl diluted lysate or BSA standard per well were diluted with buffer A’. 
After addition of 200 µl reagent B samples were incubated for 15 minutes and the OD750 
measured. Protein concentration was calculated using the BSA standard curve. 
2.2.8 SDS-PAGE 
SDS-PAA gels were cast with the Bio-Rad Mini-PROTEAN system using gels with 1.5 
mm strength. The separating gel was overlaid with water-saturated 2-butanol until polymerized. 
2-butanol was removed and washed away with H2O 5 times. The separating gel was overlaid with 
the stacking gel and a 10 or 15 well comb was added. Gels were stored wrapped in water-soaked 
paper tissues at 4°C for up to one week. The samples were mixed with 4x Lämmli buffer and 
heated to 95°C for 5 minutes. 5 µl Precision Plus Dual Color marker were used. Gels were run at 
25 mA per gel until the bromophenol blue ran out. 
2.2.9 WESTERN BLOT 
The Bio-Rad Tank blot system was used. The wet blot was assembled as shown in Figure 
4. Gels were blotted at 100V for 1h in pre-cooled transfer buffer with a cool-pack added to the 
tank. After the transfer the membrane was blocked for 2 hours shaking at room temperature in 
antibody dilution buffer (see Table 4).  
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Figure 4: Schematic of Western blot assembly for tank blot. Components are assembled as shown. The arrow indicates the 
direction in which proteins move.  
For ECL based detection, incubation with primary antibody for the protein of interest was 
done at 4°C over night. Blots were washed 3x 5 minutes with TBS-T shaking at room 
temperature before incubating with secondary antibody in blocking buffer for 1 hour at room 
temperature shaking. The membrane was washed 3x 5 minutes with TBS-T again and ECL was 
added on top of the membrane according to the manufacturer’s instructions for 3-5 minutes. 
Excess ECL reagent was drained carefully and the membrane put into a clear plastic bag that was 
taped into the X-ray cassette for development. For the loading control the membrane was put in 
stripping buffer for two hours at room temperature. After 4x washing with excess of TBS-T to 
remove the stripping buffer the membrane was blocked again and the β-actin loading control was 
done as described above. Quantification was done using Fiji142.  
When the LI-COR Odyssey CLx imaging system was used, primary antibodies for both 
the protein of interest and the β-actin loading control were incubated in parallel at 4°C over night. 
After 3x washes 5 minutes each with TBS-T, the secondary antibodies were added and incubated 
for 1 hour at room temperature protected from light. The secondary antibody was washed away 
with 3x TBS-T for 5 minutes each and directly used for detection. Quantification of the Western 
blot signals was done with LI-COR Image Studio Lite 5.2. 
2.2.10 DESIGN AND CLONING OF SHRNAS 
shRNA targeting sequences were either obtained from publications or from the Genetic 
Perturbation Platform (GPP) (http://portals.broadinstitute.org/gpp/public/). For each target 
mRNA 2-3 shRNAs from GPP were chosen based on the highest adjusted score (shRNA design 
ruleset version 9, http://portals.broadinstitute.org/gpp/public/resources/rules). The resulting 
shRNA oligos (see Table 13) were ordered from Eurofins Genomics. 
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Table 13: Design template for shRNAs. To design forward and reverse oligo the sense and antisense sequence of the shRNA 
target sequence are inserted as indicated. Annealed oligos can be cloned into pLKO.1 digested with EcoRI and AgeI.
Forward 5’ CCGG - 21 bp sense  - CTCGAG - 21 bp antisense – TTTTTG 3’ 
Reverse 5’ AATTCAAAAA - 21 bp sense – CTCGAG - 21 bp antisense 3’ 
 
5-10 µg pLKO.1 were digested with 2µl AgeI-HF (CutSmart buffer) at 37°C over night. 
The reaction was purified with the Macherey-Nagel NucleoSpin® Gel and PCR Clean-up kit. 
The DNA was then digested with 2µl EcoRI (EcoRI buffer) at 37°C over night. The sample was 
run on an agarose gel and the correct band of 7kb was cut out and purified with the same Gel and 
PCR Clean-up kit as before.  
2.5 µg forward and reverse oligo each were diluted to 50 µl in 1x NEB buffer 2 or 2.1. 
Oligos were heated to 95°C for 5 minutes and then put at room temperature to cool down slowly. 
150ng of linearized pLKO.1 were mixed with 2µl freshly annealed oligonucleotides, 2µl 10x T4 
DNA ligase buffer, and 1µl T4 DNA ligase. Ligation was done at 16°C over night. The AgeI 
restriction site is lost due to the sequence of the annealed oligonucleotides. The whole reaction 
was transformed into Subcloning Efficiency DH5α according to the manufacturer’s protocol. 
Successful cloning was controlled by AgeI-HF and NcoI restriction digest to verify removal of 
the AgeI site, and sequencing using a U6 primer. 
2.2.11 PRODUCTION AND USE OF LENTIVIRAL VECTORS 
HEK 293T cells with passage numbers below 25 were used for virus production. 5/6th of a 
fully confluent T75 flask was seeded on six 10 cm dishes in 10 ml IMDM medium. When cells 
were approximately 90% confluent, medium was changed again and cells transfected. For each 
10 cm flask a transfection mix was prepared as follows: 4 µg psPAX2, 4 µg pMD.2G, and 8 µg 
expression plasmid were diluted in 250 µl OptiMEM. 48 µl of 1 µg/µl PEI were mixed with 202 
µl OptiMEM in a separate tube. Both mixtures were combined, thoroughly mixed and incubated 
at room temperature for 20 minutes. Afterwards the transfection mix was added dropwise onto 
the cells and medium changed the next day. After three days, virus containing supernatant was 
taken, centrifuged at 1,000 rcf for 5 minutes and filtered (0.45µM). Purified virus was then 
concentrated at 134,000 rcf in an SW 32 Ti rotor or an SW 40 Ti (Beckman-Coulter) at 4°C for 2 
hours. After removal of the supernatant between 100 and 300µl OptiMEM was added and virus 
left over night at 4°C before resuspending and aliquoting virus for storage at -80°C. 
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For transduction of T84 cells 20-100 µl of concentrated lentivirus stock were diluted in 4 
ml of DMEM/F12 with 10 µg/ml polybrene and added onto very sparsely seeded cells in a 6 well 
plate. After 3 days the media was replaced with selection medium containing 5 - 10 µg/ml 
puromycin, 700 µg/ml neomycin, or 10 µg/ml blasticidin. Selection was continued until non-
transduced control cells were dead.  
2.2.12 PRODUCTION OF CHEMICALLY COMPETENT DH10BAC 
DH10Bac were cultured in 4 ml LB-kanamycin over night at 37°C shaking. This was 
used to seed 300 ml LB-kanamycin culture which was grown shaking at 37°C until an OD595 of 
0.5 was reached. Bacteria were pelleted at 1700 rcf and 4°C. From this point on all steps were 
done on ice. The supernatant was removed and bacteria resuspended in 50 ml ice-cold 50 mM 
CaCl2. After 30 minutes on ice cells were pelleted at 1700 rcf and 4°C for 15 minutes. The 
supernatant was removed and bacteria carefully resuspended in 24 ml of cryo solution (50 mM 
CaCl2 + 15% (v/v) glycerol). After 30 minutes incubation on ice 100 µl aliquots were prepared in 
pre-cooled 1.5ml microcentrifuge tubes and immediately frozen in liquid nitrogen prior to storage 
at -80°C. 
2.2.13 PRODUCTION OF RECOMBINANT BACMIDS 
The protein of interest was cloned into a Baculovirus destination with an LR reaction. A 
destination vector clone was isolated with the Macherey-Nagel NucleoSpin® Plasmid kit 
(740588.250) and transformed into chemically competent DH10Bac. 100 µl self-made competent 
DH10Bac were thawed on ice, 100-300 ng of DNA were added and bacteria incubated on ice for 
30 minutes followed by 30 seconds heat shock at 42°C and 3 minutes incubation on ice. Bacteria 
were recovered in 1 ml SOC medium and kept shaking 5 hours at 37°C. Bacteria were spun down 
at 11,000 rcf for 1 minute and spread on LB-agar plates containing 50 µg/ml kanamycin, 7 µg/ml 
gentamicin, 10 µg/ml tetracycline, 100 µg/ml X-Gal, and 40 µg/ml IPTG. After 2-3 days white 
colonies were picked and grown in 4 ml LB medium containing 50 µg/ml kanamycin, 7 µg/ml 
gentamicin, and 10 µg/ml tetracycline for another 2-3 days.  
All steps of the bacmid isolation were carried out at room temperature if not mentioned 
otherwise. 2 ml bacteria were pelleted at 3,000 rcf for 15 minutes. The pellet was resuspended in 
300 µl solution I (15 mM Tris-HCl, pH 8.0, 10 mM EDTA, 100 μg/mL RNase A) and lysed by 
addition of 300 µl solution II (0.2 N NaOH, 1% SDS). After 5 minutes the pH was neutralized by 
addition of 300µl ice cold 3M potassium acetate pH 5.5. Samples were kept on ice for 10 minutes 
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and centrifuged at 14,000 rcf. The supernatant was transferred into a new microcentrifuge tube 
containing 800 µl 2-propanol. Samples were mixed and incubated on ice for 5 – 10 minutes. 
DNA was pelleted by 20 minutes centrifugation at 14,000 rcf. The supernatant was removed and 
pellets washed in 500 µl 70% (v/v) EtOH. After a last centrifugation step of 20 minutes at 14,000 
rcf the pellet was dried and carefully resuspended in 40 µl TE buffer by flicking the tube and 
stored at 4°C. Resuspension by pipetting was avoided so as to not damage the large bacmid 
DNA. 
2.2.14 PRODUCTION AND USE OF BACMAM VECTORS 
8x105 Sf9 cells per well were seeded in 6 well plates. After one hour cells were 
sufficiently attached for transfection. The medium was replaced with 2 ml of unsupplemented 
Grace’s Insect Medium while the transfection mixes were prepared. 1 µg of bacmid DNA and 6 
µl Cellfectin II Reagent were diluted in 100 µl unsupplemented Grace’s Insect Medium each. 
Samples were combined, thoroughly mixed and incubated for 15 minutes at room temperature. 
Afterwards 800 µl unsupplemented Grace’s Insect Medium were added and the complete 
transfection mix was used to replace the medium on the insect cells. After 5 hours the 
transfection mix was replaced with 2ml Sf-900 III SFM medium.  
After 72 – 96 hours cells showed signs of late stage infection, i.e. formation of syncytia, 
cell detachment, and clear expression of recombinant proteins if they are coupled to a fluorescent 
marker. The supernatant was removed and centrifuged at 1,000 rcf for 5 minutes to remove cells 
and debris. The supernatant, the viral P1 stock, was transferred to a new tube and stored at 4°C 
protected from direct light. The complete P1 stock was used to infect 15 ml Sf9 cells in a 25 ml 
spinner flask with a density of 1.5x106/ml. After incubation of 3-5 days cells will show syncytia 
formation and recombinant protein expression. Cells were spun down at 1,000 rcf for 15 minutes, 
supernatant transferred into a new tube, and FBS added for a final concentration of 3% (v/v). 
Production of a P3 viral stock was done similar to the P2 stock with between 80 and 120 ml cells 
being infected with between 1 and 3 ml P2 stock, depending on the cell volume and quality of the 
P2 stock. P2 and P3 stocks were either stored at 4°C protected from light or concentrated by 
spinning them down at 80,000 rcf in a SW 32 Ti rotor (Beckman Coulter) for 75 minutes at 4°C. 
Afterwards the supernatant was removed and 2-4 ml Sf-900 III SFM medium with 3 % (v/v) FBS 
added. The pellet was resuspended and frozen in aliquots at -80°C.  
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2.2.15 GROWING OF REOVIRUS 
L929 cells were grown in suspension culture and kept at 7x105 cells per ml. Once a 
sufficiently large volume is reached, cells were spun down at 600 rcf for 15 minutes, resuspended 
to 2x107 cells/ml and infect with Reovirus strain Type 3 clone 9 (T3C9; originally obtained from 
Bernard N. Fields) with an MOI of 5. The virus was allowed to adsorb to for 1 hour with gentle 
shaking every 20 minutes. Then cells were diluted to 5x105 cells/ml with a 1:1 mix of fresh 
medium and conditioned medium. After 48h cell viability was assessed by trypan blue staining 
regularly until a viability of about 50% was reached. Cells were pelleted at 740 rcf, and 
resuspended in HO buffer so that 2x108 cells per 8 ml can be frozen at -80°C in a 50 ml tube. 
This is fraction represents one gradient used for purification as described below. 
2.2.16 REOVIRUS PURIFICATION 
A gradient is thawed at 37°C and then chilled on ice. Deoxycholate is added to a final 
concentration of 0.1% (w/v) and tube further incubated on ice for 10-30 minutes. 50% (v/v) -
20°C CFC-113 were added and sample emulsified with an ultrasonic homogenizer (Hielscher 
UP200Ht, power = 50W, amplitude = 100%). The sample was put back on ice to check if the 
solution remains emulsified after 30 seconds, if this was not the case then the emulsification was 
repeated. The sample was centrifuged at 9,000 rcf. The aqueous phase is transferred into a new 
tube and 40% (v/v) -20°C CFC-113 added. Homogenization and centrifugation are repeated as 
above. The aqueous phase is transferred into a new tube making sure not to transfer any of the 
CFC-113 layer. Virus was loaded on top of a cesium chloride gradient (2.5 ml each of 1.25 g/ml 
and 1.45 g/ml). Samples were centrifuged at 111,000 rcf and 4°C over night causing the 
appearance of two separate bands. The bottom of the tube was pierced to extract the lower band 
containing infectious virus. The virus is dialyzed against virus buffer over night at 4°C and then 
stored at 4°C. 
2.2.17 REOVIRUS TITRATION 
To determine infectivity of reovirus stocks the TCID50 was determined using an In-Cell 
Western. T84 cells were seeded on a 96 well plate. When confluent, cells are infected with a 1:10 
serial dilution beginning with at 1:100. Infection was done in 200 µl volume in triplicates. After 
16 hours cells are fixed with 2% (w/v) PFA in PBS for 20 minutes. PFA was removed and cells 
permeabilized two times for two minutes each with PBS + 0.1% (v/v) Triton X-100., and blocked 
with 1% (w/v) BSA in PBS for 30 minutes. Infection was detected using an antibody against the 
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viral non-structural protein µNS for 1 hour. Cells were washed twice with PBS + 0.1% (v/v) 
Tween-20. The secondary antibody (IRDye 800CW) and Draq5 were both diluted 1:10,000 in 
blocking buffer. After one hour incubation, samples were washed with three times with PBS and 
imaged using a LI-COR Odyssey CLx reader. The TCID50/ml was calculated as described by 
Hierholzer and Killington and FFU/ml approximated as described by Horzinek using a Excel 
sheet created by Marko Binder (Marco Binder, Dept. Infectious Diseases, Molecular Virology, 
Heidelberg University)143,144. 
2.2.18 PREPARATION OF ACID ETCHED COVERSLIPS 
Coverslips were transferred into a glass beaker and covered with 37% HCl. After 24 to 48 
hours the acid was removed and coverslips rinsed with H2O to neutralize the pH. Coverslips were 
stored covered in 70% EtOH. 
2.2.19 IMMUNOFLUORESCENCE  
Cells were grown on coverslips in 24 well plates. T84 cells were grown on acid etched 
coverslips, all other cells on untreated coverslips. Medium was removed, cells rinsed with PBS 
once and then fixed in 2% (w/v) paraformaldehyde for 20 min at room temperature or over night 
at 4°C. Cells were permeabilized with PBS + 0.5% (w/v) Triton X-100 for 15 minutes. 1% (w/v) 
BSA in PBS was used for blocking and dilution of the primary antibody. After one hour 
incubation, samples were washed 3x 5 minutes each with PBS + 0.1% (w/v) Tween-20. 
Secondary antibodies were diluted in PBS + BSA as well and cells incubated for 30 min. After 3x 
5 min washes with PBS + 0.1% (w/v) Tween-20, samples were rinsed in H2O and mounted on a 
microscopy slide with ProLong Gold Antifade Mountant with or without DAPI. 
For T84 cells grown on transwells, the same protocol as above was followed with the 
following changes: The membrane was cut out before the sample was put into the primary 
antibody. All washing steps were done by dipping the membrane into PBS + 0.1% Tween-20 
several times. All imaging analysis was done using Fiji142. 
2.2.20 PI(3)P STAINING 
The protocol was initially published by G. Hammond 145 and adapted by Volker Haucke 
(Leibniz-Forschungsinstitut für Molekulare Pharmakologie, Berlin). All steps are done at room 
temperature. Cells were rinsed with 1x PBS and fixed with 2% (w/v) PFA + 2% (w/v) sucrose for 
15 min. After three washes with freshly prepared 1xPBS + 50 mM NH4Cl cells were 
Materials and Methods 
47 
 
permeabilized with 20 µM Digitonin in buffer A. Cells were rinsed three times with buffer A and 
blocked (buffer A + 50 mM NH4Cl + 5% (v/v) normal goat serum (NGS)) in the presence of 
0.026 µg/ml purified GFP-FYVE for 45 minutes. After two washes with buffer A, coverslips 
were incubated in a 50 µl drop of buffer A + 5% (v/v) NGS with 1:500 dilution of rabbit anti-
GFP. Two washes for 5 min. each with buffer A were followed by 45 incubation with buffer A + 
5% (v/v) NGS + 1:200 dilution of anti-rabbit secondary antibody. Cells were washed another 
four times five minutes each with buffer A. 1 µM DAPI were added to the first washing step. 
After five minutes post-fixation with 2% PFA + 2% sucrose samples were washed another three 
times for five minutes each with PBS + 50 mM NH4Cl and mounted with ProLong Antifade 
Mountant. 
2.2.21 CELL CULTURE 
All mammalian cells were grown at 37°C with 5% CO2 in the medium given in Table 2. Sf9 
insect cells were grown in 125 ml spinner flasks (CELSTIR flask, Wheaton) at 28°C without CO2 
in a Memmert IPP55 incubator with a bioMIXdrive 4 (2mag AG) at 105 rpm. T84 cells were 
polarized by seeding them on 6.5 mm transwells with 3 µM pore polycarbonate membranes 
(Corning, 3415). 105 cells were seeded per transwell. Media was changed the next day. When the 
polarization was followed, media was changed every day and TEER measured afterwards using 
the EVOM2 epithelial voltohmmeter (World Precision Instruments). If cells only needed to 
polarize, i.e. TEER of ≥ 1000 Ω, media was changed the day after seeding and every second day 
afterwards until all transwells were polarized. 
2.2.22 LUCIFERASE ASSAY 
Cells were grown in 24 well plates. Medium was removed and cells lysed in 300 µl 
Luciferase Assay Buffer for 15 minutes at room temperature. 80 µl of lysate were transferred into 
three wells of a white, 96 well half area plate and 80 µl Luciferase Assay buffer were added to 
each well. Samples were mixed thoroughly and luciferase activity read with a Tecan Infinite 200 
Pro without attenuation with one second integration time and without settle time. Average and 
standard deviation of each sample triplicate were used. 
2.2.23 ELISA 
ELISA for IFNλ, IL-6, and IL-8 was done to the manufacturer’s instructions with the 
exception of halving all volumes as half area plates were used. For IL-6 and IL-8 samples were 
diluted 1:2, for IFNλ 1:5.  
Materials and Methods 
48 
 
2.2.24 FLOW CYTOMETRY ANALYSIS OF TRANSGENE EXPRESSION 
Samples were taken during routine passaging and transferred into a test tube with cell 
strainer cap. Cells were analyzed on a BD FACS Canto II. Side scatter, front scatter, and 
fluorescence were adjusted using wildtype cells. Between 10,000 and 50,000 cells were used. 
Analysis was done with FlowJo 10. 
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3 RESULTS 
3.1 VPS34 INHIBITION 
3.1.1 VERIFY EFFICIENCY OF VPS34-IN1 AND SAR405 IN T84 CELLS 
The aim of this project is to manipulate endosomal PI(3)P levels to elucidate the role of 
this lipid pool in cellular polarity and in regulating innate immune responses. The fastest way to 
assess this question is by inhibitor treatment. The two major players in establishing and 
maintaining the endosomal PI(3)P pool are the PI3-kinase vacuolar sorting protein 34 (VPS34, 
PIK3C3) and phosphatases of the myotubularin family (MTMs)146. The VPS34 inhibitors 
VPS34-IN1 and SAR405 were chosen due to their specificity147,148. To verify that these two 
inhibitors work in our system, we performed an indirect immunofluorescence assay to control for 
the depletion of PI(3)P. However, the PIP antibody did not lead to any detectable staining. Due to 
the low transfection efficiency of our polarized T84 cells (Sup. Figure 1) we chose an alternative 
staining approach that combines a purified PIP-binding domain with antibody staining (Figure 5 
A). A purified PI(3)P binding protein domain coupled to GFP was added during the blocking 
step. This was subsequently detected with a GFP antibody and a fluorescently tagged secondary 
antibody. This approach results a punctuate staining in A549 cells largely overlapping with early 
endosomes stained with the early endosome antigen 1 (EEA1) (Figure 5 B). 
 
Figure 5: Staining protocol for endosomal PI(3)P. A) Schematic of the protocol. PI(3)P is bound by purified FYVE-GFP which 
is subsequently detected with an anti-GFP antibody and an Alexa Fluor coupled secondary antibody. B) Example of endosomal 
PI(3)P staining in A549 cells. The lipid pool (PI(3)P) shows strong similarity to early endosome antigen 1 (EEA) was a marker 
for early endosomes. Scale bar: 12 µM. 
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After confirmation of our staining approach, T84 cells were either mock treated (DMSO) 
or treated with 1 µM or 5 µM VPS34-IN1 for 15 minutes, 16 hours, and 24 hours and stained for 
PI(3)P (Figure 6). These times were chosen to test if the inhibitor has a fast mode of action or if 
longer pre-treatment will be necessary for further experiments (15 minutes), as a control for the 
time needed for a single viral lifecycle (16 hours), and to determine if we will be able to culture 
cells for a longer period of time with daily media changes to replenish the inhibitor (24 hours). 
Mock treated samples show punctuated signals corresponding to endosomal markers such as 
EEA1 (Figure 5 B) or Rab5149–152. These pools are severely reduced after only 15 minutes with 1 
µM VPS34-IN1 (Figure 6 A). As the staining does not re-appear after 16 or 24 hours, overnight 
treatments or polarization timecourses with daily media changes will be possible. Specificity and 
off-target effects of VPS34-IN1 were tested with concentrations of up to 1 µM in the original 
publication. On the microscope, or by increasing the contrast, one can clearly see that the PI(3)P 
pools are still there only with a lower intensity (Figure 6 B)148. Therefore we tested a higher 
concentration as well. 5 µM VPS34-IN1 decreases the PI(3)P signal within 15 minutes and up to 
24 hours (Figure 6 A). But unlike 1 µM VPS34-IN1 even with increased contrast no remaining 
PI(3)P staining can be observed (Figure 6 B). 
 
Figure 6: Timecourse experiment using the VPS34 inhibitor VPS34-IN1 in T84 cells. A) PI(3)P indirect immunofluorescence 
of T84 cells that were either mock treated (DMSO) or treated with VPS34-IN1 for 15 minutes, 16 hours, or 24 hours. B) Same 
images as in A but with increased brightness and contrast. All images show a z-stack maximum intensity projection of 
representative cells. Scale bar: 25 µM.  
Results 
51 
 
The second inhibitor, SAR405, has been reported to be very specific with an IC50 of 1.5 
nM for VPS34 while other class I and class II PI3-kinases as well as mTOR are inhibited with 
IC50 values of over 10 µM
147. This inhibitor was tested in a similar manner as the VPS34-IN1. 1 
µM was chosen as it is at the lower range of activity in our system (see Figure 7). 6 µM was 
chosen because it is the concentration that was used to show the importance of VPS34 in 
epithelial integrity using spheroid formation in the related colon carcinoma cell line Caco-2103. 
As seen for VPS34-IN1, a 15 minute incubation with 1 µM SAR405 strongly reduces the PI(3)P 
pools. An effect that can still be observed up to 24 hours, allowing for a rapid removal of PI(3)P 
as well as overnight treatments (Figure 7 A). As with VPS34-IN1, remaining signal can be 
observed (Figure 7 B). When 6 µM SAR405 was used only an unspecific background can be seen 
(Figure 7). 
 
Figure 7: Timecourse experiment using the VPS34 inhibitor SAR405 in T84 cells.  A) PI(3)P indirect immunofluorescence in 
T84 cells that were either mock treated (DMSO) or treated with SAR405 for 15 minutes, 16 hours, or 24 hours. B) Same images 
as in A but with increased brightness and contrast. All images show a maximum intensity projection of a Z-stack of representative 
cells. Scale bar: 25 µM. 
This data show that both inhibitors work in T84 cells and that inhibition results in a fast 
reduction in PI(3)P levels after only 15 minutes while still maintaining activity after 24 hours 
(Figure 6 and Figure 7).  
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3.1.2 VPS34 INHIBITION AND POLARIZATION 
As a first set of experiments the impact of inhibitor mediated PI(3)P depletion on 
polarization was tested. Polarity in intestinal epithelial cells refers to the asymmetrical 
distribution of lipids, proteins, RNA, and organelles along the apico-basal axis. Polarity can be 
monitored by marker proteins of the apical or basolateral membranes. However, due to the need 
to polarize T84s on non-transparent transwell inserts were are unable to monitor the process of 
polarization live and fixation of these samples will not allow us to follow the same cell 
population over time153–155. Therefore we decided to use a less invasive way of measuring 
polarity: the trans-epithelial electrical resistance (TEER). When T84 cells are grown on 
permeable transwell inserts, over time they will form an epithelial layer with cell-cell connections 
and polarize (Figure 8 A). The tight junctions in between the cells act as a barrier between the 
apical and basal compartment creating an electrical resistance between the compartments that can 
be monitored over the course of an experiment (Figure 8 B). As described in the introduction, 
there is a strong link between polarity and properly formed tight-junctions. Therefore the buildup 
of the TEER can be used to follow formation of tight-junctions, which in turn can serve as a 
marker of polarity (Figure 8 C). In our setting, using T84 cells on 6.5 mm transwells with 3 µM 
pores, we consider the epithelium tight and cells polarized at 1000 Ohm. Furthermore, it is an 
important readout as it tells us if there is a tight monolayer that prevents passive diffusion. This is 
a prerequisite if cells are to be infected from either the apical or basal site which requires an 
intact monolayer to maintain this separation. 
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Figure 8: Schematic of how formation of a polarized epithelium is monitored. A) Schematic of experimental setup. Cells are 
grown on the permeable membrane of a transwell insert. Formation of the tight-junctions will separate the apical from the basal 
compartment. Using electrodes the trans-epithelial electrical resistance (TEER) can be measured. B) Example of fully formed 
tight junctions in T84 cells by staining the tight-junction protein ZO-1. Scale bar: 12 µM. C) Schematic of the development of 
TEER over time and experimental setup for polarization of inhibitor treated cells. The dashed line at 1000 Ohm indicates when 
tight junctions of the epithelium are considered to be formed. Medium is changed every day and cells are either mock treated or 
treated with inhibitor at different times post seeding. Cells are then kept in inhibitor until the end of the experiment. 
To follow polarization, T84 cells were seeded on transwells. Medium was changed the 
next day and fresh medium containing either DMSO (black lines) or 1 µM VPS34-IN1 (red lines) 
was added to the transwells. While control cells polarized normally (Figure 9 A), addition of the 
inhibitor on day 1 post seeding inhibited the rate of polarization (Figure 9 B). The same trend can 
be seen when the inhibitor was added at day 3 post seeding (Figure 9 C). Interestingly, when the 
inhibitor was added to fully polarized cells, 6 days post seeding, a fast response to the drug can 
be observed and the TEER increase is severely hampered. (Figure 9 D). 
 
 
Figure 9: T84 wildtype polarization with 1 µM VPS34-IN1. T84 cells were seeded onto transwell inserts. 24 hours post-
seeding medium was change and replaced with either DMSO (A) or treated with 1 µM VPS34-IN1 beginning at day 1 (B), day 3 
(C), or day 6 (D) after seeding and kept with inhibitor for the remainder of the experiment. For each condition two transwells 
were used. The average and standard deviation are shown. One representative experiment is shown, see Sup. Figure 2 for full 
dataset. 
Results 
54 
 
Even though treatment with 1 µM VPS34-IN1 had a clear impact on the TEER (Figure 9), 
cells still were able to polarize, meaning they reached TEER values of over 1000 Ohm. As 
treatment with 1 µM VPS34-IN1 only decreases the endosomal PI(3)P pool, the experiment was 
repeated using 5 µM VPS34-IN1 which was shown to completely remove endosomal PI(3)P 
(Figure 10).  
 
Figure 10: T84 wildtype polarization with 5 µM VPS34-IN1. T84 cells were seeded onto transwell inserts. 24 hours post-
seeding medium was change and replaced with either DMSO (A) or treated with 5 µM VPS34-IN1 beginning at day 1 (B), day 3 
(C), or day 6 (D) post seeding and kept with inhibitor for the remainder of the experiment. For each condition two transwells were 
used. The average and standard deviation are shown. One representative experiment is shown. See Sup. Figure 3 for full dataset. 
As before, mock cells polarized normally (Figure 10 A). But unlike when cells were 
treated with 1 µM VPS34-IN1, addition of 5 µM VPS34-IN1 at day 1 post seeding prevented 
cells from polarizing as seen by the low TEER (Figure 10 B). The effect on TEER development 
is even more pronounced compared to 1 µM VPS34-IN1 when the inhibitor is added 3 or 6 days 
post seeding (Figure 10 C and D). TEER development is not only slowed down or stalled, it even 
decreases. This is especially pronounced when VPS34 is inhibited 6 days post seeding (Figure 10 
D). 
Previous results have shown that reducing the endosomal PI(3)P pool by VPS34 
inhibition slows down polarization (Figure 9 and Figure 10) and even reduces TEER after cells 
have clearly polarized (Figure 10 D). To verify that the results are due to VPS34 inhibition and 
not off-target effects, the polarization timecourse was repeated with a second inhibitor, SAR405. 
Here we have chosen to use 6 µM as it is the concentration where the endosomal PI(3)P pool is 
completely depleted (Figure 7), and this concentration was used to show the importance of 
VPS34 on epithelial integrity in a similar cell line103. As with the previous experiments, addition 
of the inhibitor 24 hours post seeding prevents normal polarization with cells barely getting over 
1000 Ohm (Figure 11 B) and much slower development compared to mock treated cells (Figure 
11 A). Addition of SAR405 3 days after seeding slows down polarization compared to mock 
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treated cells but the TEER still increases over time (Figure 11 C), and if the inhibitor is added 
when high TEER values have been reached, between 6000 and 7000 Ohm, the TEER drops 
slightly over the next few days (Figure 11 D). 
 
Figure 11: T84 wildtype polarization with 6 µM SAR405. T84 cells were seeded onto transwell inserts. 24 hours post-seeding 
medium was change and replaced with either DMSO (A) or treated with 6 µM SAR405 beginning at day 1 (B), day 3 (C), or day 
6 (D) post seeding and kept with inhibitor for the remainder of the experiment. For each condition two transwells were used. The 
average and standard deviation are shown. One representative experiment shown, see Sup. Figure 4 for full dataset. 
To exclude that low or dropping TEER values, especially after 5 µM VPS34-IN1 and 6 
µM SAR405 treatment, were not due to cell death, the membranes were stained with DAPI at the 
end of the experiment (Figure 12). Only when treated at day one monolayers had holes. 
Treatment at any other time still allowed cells to form monolayers. 
 
Figure 12: DAPI staining of cells treated with 5 µM VPS34-IN1 for nine days. Cells were stained with DAPI at the end of the 
experiment. One representative example is shown for the experiment with the strongest impact on polarity (Sup. Figure 3 A). 
Scale bar: 75 µM. 
Together these results show that PI(3)P is critical for polarization in our T84 cell model. 
Complete removal of PI(3)P greatly impacts the cells ability to form and maintain their polarized 
nature, while even low levels of PI(3)P are sufficient to maintain polarity. 
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3.1.3 VPS34 INHIBITION AND IMMUNITY 
Due to the role of PI(3)P, in polarity and epithelial integrity, endosomal trafficking, and 
TLR signaling, we wanted to test the impact of inhibitor mediated PI(3)P depletion on 
mammalian reovirus (MRV) Type 3 Dearing (T3D) infection86,92,93,103,108,109,156. Previous work in 
the lab has determined that T3D is capable of infecting T84 cells from both their apical and 
basolateral membranes157,158. After virus entry and uptake, the viruses are trafficked into the 
endosome where they are further processed and released into the cytosol for viral replication to 
begin. During the course of infection, T3D is detected by the innate immune system through the 
Toll-like receptors within the endosome159. This detection leads to the induction of cytokines, 
which can be detected through an ELISA readout. Three different ELISA read-outs, IFNλ, IL-6 
and IL-8, have been chosen due to their induction following viral infection and their importance 
in epithelial cells. Interferon lambda (IFNλ), also known as interferon type 3 (IFN3), mainly acts 
on epithelial cells due to the restricted expression of its receptor160. Additionally, work in the lab 
has shown that IFNλ protects intestinal cells from T3D infection and its protective activity 
extends to the intestinal epithelium, even to rotavirus infection, a virus closely related to MRV161. 
Interleukin-6 (IL-6) was shown to be produced by numerous cells, including IECs, and is 
involved in tissue repair162,163. Interleukin-8 (IL—8) is produced by IECs as well and acts as a 
chemoattractant for neutrophils, natural killer cells (NK cells), T cells etc 164. 
Initially we wanted to determine whether cells required pre-treatment with the inhibitors 
prior to infection and which time post-infection lead to the highest induction of cytokines. T84 
cells were seeded and allowed to attach over night. The next morning they were pre-treated with 
either with 5 µM VPS34-IN1 or mock treated (DMSO) for one hour. Afterwards cells were 
infected with reovirus for 16 or 24 hours in the presence of absence of 5 µM VPS34-IN1. The 
ELISA results for IFNλ, IL-6, and IL-8 show that 24 hours post-infection leads to the largest 
induction of all cytokines. Interestingly, addition of 5 µM VPS34-IN1 reduces the cells immune 
response for all three cytokines (Figure 13). Furthermore it is apparent that pre-stimulation for 
one hour does not result in a greater reduction compared to cells which received the inhibitor at 
the same time as infection. This fits well with the rapid effect of VPS34-IN1 as can be seen in 
Figure 6. As SAR405 acts as rapidly as VPS34-IN1 (Figure 6 and Figure 7), we decided to 
continue all experiments without inhibitor pre-treatment. 
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Figure 13: Determination of timing of inhibitor addition. T84 cells were seeded 24 hours prior to infection. Cells were pre-
treated with DMSO or 5 µM VPS34-IN1 and then subsequently infected with T3D. Samples were harvested after 16 and 24 hours 
and used for ELISA analysis. Data of technical triplicates shown. 
To determine if the SAR405 also inhibits the production of cytokines after T3D infection 
we used a similar protocol as described above. T84 cells were seeded 24 hours prior to infection 
and cells were treated with DMSO or 6 µM SAR405 for 24 hours (Figure 14). However, unlike 
the VPS34-IN1, the SAR405 inhibitor led to an increase in the production of all three cytokines. 
A similar increase in cytokine production, e.g. IL-6, upon TLR2 and TLR4 stimulation of bone 
marrow derived dendritic cells (BMDCs) upon SAR405 treatment has been shown165. But in this 
publication, BDMCs treated with 1 µM VPS34-IN1 also had an increased immune response, 
unlike what we have seen with 5 µM VPS34-IN1 in T84 cells (Figure 13). This difference 
between the two inhibitors in T84 cells as well as between T84 cells and BMDCs could be due to 
off-target effects when using a high concentration of either inhibitor (Figure 13).  
 
Figure 14: VPS34 inhibition with 6 µM SAR405 and immunity to reovirus infection. T84 cells were seeded 24 hours prior to 
infection. Cells were infected with T3D in the presence or absence of 6 µM SAR405. Samples were harvested after 24 hours and 
used for ELISA analysis. Results for IFNλ, IL-6, and IL-8 show a significant increase in the immune response. N=12, significance 
was tested with an unpaired, two-tailed t-test. P > 0.05; * = P ≤ 0.05; ** = P ≤ 0.01; *** = P < 0.001. 
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To further investigate the possibility of side effects of the inhibitors used, the experiment 
was repeated using 1 µM VPS34-IN1 (Figure 15). Once a lower inhibitor concentration was used, 
the previously observed reduced immune response could not be reproduced, and cells treated 
with a lower VPS34-IN1 concentration showed no significant change in the immune response for 
all three cytokines tested. 
 
 
Figure 15: VPS34 inhibition with 1 µM VPS34-IN1 and immunity to reovirus infection. T84 cells were seeded 24 hours prior 
to infection. Cells were infected with T3D in the presence or absence of 1 µM VPS34-IN1. Samples were harvested after 24 hours 
and used for ELISA analysis. Results for IFNλ, IL-6, and IL-8 show no significant increase in the immune response. N=12, 
significance was tested with an unpaired, two-tailed t-test. ns = not significant. P > 0.05; * = P ≤ 0.05; ** = P ≤ 0.01; *** = P < 
0.001. 
Lastly, we wanted to test the impact of the inhibitors on the viral infectivity. Therefore T84 
cells were infected with a serial dilution of reovirus T3D in the presence or absence of both 
inhibitors. Infectivity was determined by staining the viral non-structural protein µNS. Relative 
infectivity was determined by comparison of inhibitor treated samples to mock treated infections 
(Figure 16). While both inhibitors seem to reduce the infectivity of reovirus T3D in T84 cells at 
the concentrations used for the experiments above, these results are not significant. 
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Figure 16: Relative infectivity of reovirus in presence 
of VPS34 inhibitors. Cells were infected with serial 
dilutions of reovirus T3D in the presence or absence of 
both inhibitors. Infection was determined by 
immunofluorescence analysis of the non-structural 
protein µNS. Infectivity is shown relative to non inhibitor 
treated samples (mock). Average and standard deviation 
of two independent experiments with technical triplicates 
are shown. 
These results show that both inhibitors prevent or slow down polarization, as indicated by 
the decreased TEER (Figure 9, Figure 10, and Figure 11). Their impact on immunity on the other 
hand is inconclusive and would argue for off-target effects (Figure 13, Figure 14, and Figure 15). 
While a reduced immune response at 5 µM VPS34-IN1 would fit well with the lower infectivity 
(Figure 13), 1 µM VPS34-IN1 also reduces infectivity but does not change the immune response 
(Figure 15), and the reduced infectivity of SAR405 even results in a higher immune response 
(Figure 14). This further indicates that these results are not significant (Figure 16). 
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3.2 KNOCK-DOWN OF VPS34 AND MTM1 
3.2.1 VERIFICATION OF KNOCK-DOWN EFFICIENCY IN T84 CELLS 
As our previous results indicate that the inhibitors lead to off target effects we chose to 
evaluate the role of PI(3)P by knock-down its metabolizing enzymes103,149,166. The two major 
players in early endosome PI(3)P metabolism are the PI3-kinase VPS34 and the PI3-
phosphatases of the MTM family, especially MTM191. Loss of MTM1 is associated with x-linked 
myotubular myopathy (XLMTM) and the XLMTM patient derived cell line shows defective 
transferrin exocytosis and endosomal β1-integrin accumulation. Also increased PI(3)P levels on 
early endosomes and impaired recycling from endosomes to the plasma membrane have been 
reported78,91,146,167. In total, two shRNAs against MTM1 and three shRNAs against VPS34 were 
chosen. The targeting sequences were either taken from the database of the Genetic Perturbation 
Portal (GPP) of the Broad Institute (shMTM1 #1, shVPS34 #1 and shVPS34 #2) or based on 
previously published siRNA sequences (shMTM1 #2 and shVPS34 #3)78,168. T84 cells were 
transduced by lentiviral vectors expressing one of the shRNAs or a scrambled control shRNA 
As epithelial cells, T84 cells tend to grow close to one another and form cell-cell- 
connections as they would in an epithelium. We have seen before that T84 cells have a reduced 
metabolism when they have sufficient cell- cell contacts. Once cells grow as a tight epithelium or 
in islands close to one another they are poorly transduced by viral vectors, or at least show little 
to no trans-gene expression. We also observed that while sparse cells can be easily selected by 5 
µg/ml puromycin, a confluent monolayer of T84 cells can survive several days in 20 µg/ml 
puromycin. Furthermore, during my master thesis I have shown that knock-down by several 
rounds AAV-delivered shRNAs does reduce the mRNA levels but does not have an impact on the 
protein. Only when we used lentiviral vectors and several rounds of passaging cells at low 
confluency, protein levels decreased (Sup. Figure 5). Therefore, to achieve an efficient knock-
down, we need to transduce and select T84 cells at a very low density and split regularly to 
maintain a relatively low density for at least two weeks before we can detect a clear knock-down. 
At this time, cells were harvested and the expression level of VPS34 and MTM1 were assessed 
(Figure 17 A). Compared to the scrambled shRNA control, all shRNAs with the exception 
shVPS34 #1 had reduced the mRNA levels to less than 30%. Based on these results, cell lines 
expressing shMTM1 #1 or shVPS34 #3 were used. Additionally, to confirm that the knock-down 
was maintained through serially passaging of our cells, a second confirmation of both the mRNA 
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and protein levels was performed. While the mRNA levels were slightly higher than the original 
screen, around 27% in both lines, Western blots confirmed that the proteins were reduced (Figure 
15 B and C). Taken together, these results show that knock-down cell lines were successfully 
established. 
 
Figure 17: Knock-down of MTM1 and VPS34 in T84 cells. A) T84 cells transduced by lentiviruses expressing shRNAs against 
VPS34 or MTM1 were validated by qPCR. All five shRNAs were tested in order to determine with which cell line to continue. 
Expression is shown relative to a scrambled shRNA. B) MTM1 mRNA and protein levels in scrambled control, shMTM1, and 
shVPS34 knock-down cell lines. C) VPS34 RNA and protein levels in scrambled control, shVPS34, and shMTM1 cell lines. 
Relative expression of the protein was calculated by band intensities and using the actin signal for normalization. 
3.2.2 VPS34 AND MTM1 KNOCK-DOWN IN POLARITY 
As with the VPS34 inhibitor experiments, we assessed the role of VPS34 and MTM1 on 
the ability of T84 cells to polarize. T84 cells knocked-down for VPS34 or MTM1 were seeded on 
transwells and their TEER was evaluated over polarization. Development of the TEER was 
followed for nine to ten days in three independent experiments (Figure 18). All three cell lines 
were still able to polarize as shown by the TEER values of over 1000 Ohm. The scrambled 
control cells polarize as like wildtype cells. They reach a polarized state within two to three days 
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and are able to build up high TEER values. The MTM1 knock-down cells behave very similar, 
possibly polarizing slightly faster. VPS34 knock down cells on the other hand clearly polarize 
slower and do not reach as high TEER values 
 
Figure 18: Polarization timecourses of MTM1 and VPS34 knock-down cells.  T84 cells expressing shScrabled or knock-down 
shRNA for either MTM1 or VPS34 were seeded onto transwells. For each experiment, all three cell lines were seeded at identical 
density seeded on four transwells. Polarization was followed for nine to ten days. Three independent polarization timecourse 
experiments are shown. Average and standard deviation are shown. 
3.2.3 VPS34 AND MTM1 KNOCK-DOWN IN IMMUNITY 
Next, the impact of both knock-downs on immunity was tested. For that, T84 cells were 
infected with reovirus T3D as for the inhibitor experiments before and supernatants harvested 
after 24 hours. The immune response was tested by ELISA for IFNλ, IL-6, and IL-8 (Figure 19). 
IFNλ expression increased in MTM1 knock-down cells while the response decreased in VPS34 
knock-down cells. The increased response to the MTM1 knock-down was also observed for IL-6 
but VPS34 knock-down did not change the IL-6 levels. The results for IL-8 were slightly more 
difficult to interpret as individual samples show a much higher spread but overall it seems that 
the IL-8 levels are slightly reduced in both knock-downs. In summary, we have shown a role for 
VPS34 in polarity as well as for VPS34 and MTM1 in the innate immune response. 
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Figure 19: Immune response in MTM1 and VPS34 knock-down cell lines.  T84 cells expressing a scrambled shRNA, 
shMTM1 or shVPS34 were infected with reovirus T3D. Supernatants were harvested 24 hours later and analyzed for IFNλ, IL-6, 
and IL-8. A and B show results from two different ELISA plates per readout. N=4 per plate, significance was tested with a two-
tailed, unpaired t-test: ns = not significant, P > 0.05; * = P ≤ 0.05; ** = P ≤ 0.01; *** = P < 0.001. 
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3.3 CHEMICALLY INDUCED DIMERIZATION SYSTEM TO REDUCE EARLY ENDOSOME 
PI(3)P LEVEL 
3.3.1 VERIFICATION THE CHEMICALLY INDUCED DIMERIZATION SYSTEM WORKS 
So far we have used two different methods of interfering with the cellular PI(3)P levels, 
either by chemical inhibition or knock-down of metabolizing enzymes. Both methods have 
yielded different results, e.g. the stronger impact on TEER development upon SAR405 treatment 
compared to knock-down (Figure 11 and Figure 18) or an increased immune response upon 
SAR405 treatment while VPS34 knock-down either reduces the IFNλ and IL-8 response and does 
not change the IL-6 response (Figure 14 and Figure 19). Besides the possibility of off-target 
effects of the inhibitors, the difference between inhibition and knock-down could result from the 
fact that the inhibitors only reduce the lipid level while a knock-down reduces protein level. As 
both of these proteins also interact with other proteins, loss of a protein could have an impact 
beyond the loss of its catalytic activity96,169. Also, VPS34 is part of two different complexes. 
Complex I is found on phagosomal/autophagosomal membranes while complex II is found on 
endosomal membranes96,147,170. Both methods used for target VPS34 in general, thereby 
interfering with both complexes. To prevent that, we decided to continue with a method allowing 
us to change PI(3)P composition in a more precise way. 
We chose to remove PI(3)P from early endosomes because it is the predominant 
phosphoinositide and has been shown to be involved in processes such as maturation from early 
to late endosomes, endocytosis in hepatocytes, and EGF receptor signaling86,146,148,150,171–173. 
Therefore targeting early endosomes should impact cellular trafficking which is necessary for 
polarity and polarized sorting. We decided to utilize a chemical dimerization system to 
specifically remove PI(3)P from early endosomal membranes (Figure 20). Rapamycin is a small, 
cell permeable molecule used as an immunosuppressant. It acts by binding the FK506 Binding 
Protein 1A, 12kDa (FKBP12) which then inhibits mTOR by binding to its FKBP and rapamycin 
binding (FRB) domain174. To use this as a tool, we fused the FRB domain to Rab5 and the FKBP 
domain to the PI(3)P phosphatase MTM1. We utilized a mutated FRB domain, FRB*, so we can 
use AP21967 (rapalog) which does not interact with mTOR (Figure 20 A)174. If rapalog is added, 
it forms a complex with FRB* and FKBP which recruits MTM1 to the early endosome. We used 
either full-length wildtype (wt) human MTM1 or full-length human MTM1-C375S, a 
phosphatase-dead mutant that has been previously characterized175,176. 
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Figure 20: Schematic of the chemically induced dimerization system. A) Cells express the early endosome marker Rab5 as an 
anchor. Rab5 is fused to GFP and the FRB* domain (Rab5-GFP-FRB*). The enzyme MTM1 is linked to the FKBP domain and 
mRFP (mRFP-FKBP-MTM1). The enzyme is cytoplasmic and does not remove the endosomal PI(3)P. B) When the chemical 
dimerizer (rapalog) is added it forms a trimeric complex with the FRB* and FKBP domain recruiting the enzyme to the endosome 
which depletes the PI(3)P pool.  
To prove the functionality of this system, we need to be able to detect the loss of PI(3)P 
on early endosomes upon recruitment of MTM1 wildtype but not MTM1-C375S. Unfortunately 
we cannot use the staining procedure described above as it uses an GFP antibody to detect PI(3)P 
(Figure 5 A) and the Rab5 anchor is GFP-tagged as well (Figure 20). Therefore chose an indirect 
approach using changes in endosome morphology upon PI(3)P depletion. Enlarged endosomes 
and tubularization have been described before upon VPS34 knock-down and PI(3)P depletion by 
MTM1 using a chemical dimerization approach171,177. To test this in our hands, we used HEK 
293T cells. Unlike T84 cells, they can easily be transfected with a PI(3)P sensor thus obviate the 
need to stain PI(3)P by immunofluorescence. HEK 293T cells were transfected with Rab5-CFP-
FRB*, mRFP-FKBP-MTM1-wt or MTM1-C375S, and FYVE-GFP as a PI(3)P sensor (Figure 
21). Without inducing dimerization, the Rab5 anchor shows the expected punctuate structures 
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fitting well with its endosomal localization. Also Rab5 anchor localization overlaps with the 
signal from the PI(3)P sensor FYVE-GFP (Figure 21 A, top panel). Upon addition of the 
dimerizer (rapalog), the cytoplasmic enzyme is recruited to the endosomes thereby changing their 
morphology and the PI(3)P signal becomes dispersed within the cell (Figure 21 A, lower panel). 
When the same experiment is performed with the catalytically inactive C375S mutant, PI(3)P 
levels are not depleted and endosome morphology remains unchanged (Figure 21 B). This proves 
that our system can remove PI(3)P when MTM1-wt but not MTM1-C375S is recruited and that 
this results in morphological changes of the early endosomes. Next, the same cell lines were 
treated with 6 µM SAR405, a concentration sufficient for decreasing PI(3)P levels (Figure 7). In 
this experiment enlarged endosomes upon PI(3)P depletion can be observed as well, further 
strengthening the argument that loss of PI(3)P but not recruitment of an enzyme by itself is the 
reason (Figure 21 C). The same changes in early endosome morphology can be seen in T84 cells 
expressing Rab5-GFP-FRB* anchor and mRFP-FKBP-MTM1-wt. Upon addition of the 
dimerizer (rapalog) MTM1 is recruited to early endosomes which become enlarged (Figure 21 
D). Therefore confirming that the system can be used to deplete PI(3)P from early endosomes in 
T84 cells. 
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Figure 21: Proof of principle of the chemically induced dimerization system. A) HEK 293T expressing Rab5-CFP-FRB* 
anchor, mRFP-FKBP-MTM1-wt, and FYVE-GFP were treated with EtOH or rapalog for two hours. Cells were fixed and 
observed by epifluorescence. B) Experiment as in A but with MTM1-C375S. C) HEK 293T cells expressing Rab5-CFP and 
FYVE-GFP treated with 6 µM SAR405 for 60 minutes. D) Same as A expect using T84 cells. A-D Representative image is 
shown. Scale bar: 10 µM. 
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3.3.2 EARLY ENDOSOME PI(3)P DEPLETION AND POLARIZATION 
After establishment of T84 cell lines expressing both the Rab5-GFP-FRB* anchor and 
either MTM1-wt or MTM1-C375S, we tested the importance of endosomal PI(3)P on 
polarization (Figure 22). We used a similar experimental set-up as was previously used in the our 
VPS34 inhibitor treated cells (Figure 8 C), where the dimerizer was added at different times after 
seeding (1d, 4d, and 7d for Rab5 + MTM1 expressing cells; 1d, 3, and 6d for T84 wildtype cells) 
and polarization was followed for up to 12 days. Cells expressing the Rab5 anchor and wildtype 
MTM1 polarize when dimerization is not induced (Figure 22 A) while induction of dimerization 
and depletion of PI(3)P by addition of rapalog one day after seeding prevents polarization. When 
PI(3)P is depleted after cells are polarized (TEER > 1000 Ohm) there is only very little increase 
in TEER compared to the mock control (see Sup. Figure 6 for full dataset). When the experiment 
is done with cells expressing the Rab5 anchor but the phosphatase dead MTM1-C375S, the 
results are very similar to cells expressing the wildtype enzyme (Figure 22 B). If the recruitment 
is induced one day after seeding cells do not polarize anymore and when it is added after cells are 
polarized the TEER does not increase anymore (see Sup. Figure 7 for full dataset). To test 
whether this is due to phosphatase-independent functions of MTM1, because MTM1-C375S 
forms heptameric rings with endogenous wildtype MTM1 stimulating its activity178, or the 
dimerizer itself, we tested polarization of T84 wildtype cells in the presence of rapalog (Figure 22 
C). As with the MTM1 expressing cell lines, addition of rapalog one day after seeding prevents 
polarization. Also addition at later timepoints does interfere with the TEER values, which 
develop slower and do not reach as high values as the control cells (see Sup. Figure 8 for full 
dataset). This argues that the effect on polarization we see in cells expressing the chemical 
dimerizer system is at least partly due to the dimerizer itself. 
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Figure 22: T84 cell polarization upon MTM1-mediated PI(3)P depletion. T84 cells expressing the early endosome anchor 
(Rab5-GFP-FRB*) were seeded onto transwell inserts and allowed to polarize. Rapalog was added at indicated times post-
seeding. (A) T84 also express recruitable MTM1 wildtype or (B) phosphatase dead MTM1-C375S. (C) T84 wildtype cells were 
used as a control. (A-C) Polarization was followed by measuring the TEER. Every condition was done in duplicates and the 
average and standard deviation are shown. 
3.3.3 EARLY ENDOSOME PI(3)P DEPLETION AND IMMUNITY 
Next we wanted to test the impact of PI(3)P depletion on Rab5-positive early endosomes 
on the immune response. To that end, T84 cells expressing the Rab5 anchor and either MTM1 
wildtype or MTM1-C375S were used. As we knew from the previous experiment that the 
chemical dimerizer itself is sufficient to interfere with polarization (Figure 22 C), we also 
included T84 wildtype cells. All cells were seeded at identical numbers and infected with 
reovirus T3D 24 hours post-seeding. Supernatants were harvested at 24 hours post infection to 
analyze the immune response by ELISA for IFNλ, IL-6, and IL-8 (Figure 23). 
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Figure 23: Immune response upon PI(3)P depletion by rapalog. T84 cells expressing Rab5 anchor and MTM1-wildtype, Rab5 
anchor and MTM1-C375S, or T84 wildtype were infected in the presence and absence of the chemical dimerizer (rapalog). 
Supernatants were harvested 24 hours post infection and ELISA for IFNλ, IL-6, and IL-8 were used as readouts. Significance was 
tested with an unpaired two-tailed t-test. Only significant changes are shown with P > 0.05; * = P ≤ 0.05; ** = P ≤ 0.01; *** = P < 
0.001. 
We observed a significant reduction in the IFNλ, IL-6, and IL-8 response when 
dimerization was induced by addition of rapalog (Figure 23). This reduction was independent of 
whether wildtype MTM1 or the phosphatase dead MTM1-C375S was recruited to endosomes. 
The same phenotype could also be observed in the T84 wildtype control cells. This argues that 
the phenotype is not dependent on PI(3)P but the dimerizer itself. Interestingly, when comparing 
the immune response in the three cell lines without addition of rapalog, cells expressing MTM1-
C375S have a lower IFNλ response than T84 wildtype cells and both cells expressing MTM1-wt 
or MTM1-C375S show a significantly lower IL-6 response compared to T84 wildtype cells 
(Figure 23). 
The experiments presented in this thesis argue for impaired polarization upon PI(3)P 
depletion by VPS34 inhibition or knock down. This is in concert with previously published 
results showing the importance of VPS34 for epithelial integrity103. Importance of PI(3)P on 
immunity was not as clear due to inconsistent results when using two different VPS34 inhibitors 
or knock down of MTM1 and VPS34. Also we observed that in our system chemical 
dimerization posed a problem as the dimerizer itself interferes with polarization and immunity. 
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3.4 CREATION OF NEW BACMAM VIRAL VECTORS 
3.4.1 PERSISTENT BACMAM VECTOR 
Viral vectors based on Baculoviruses with mammalian expression cassettes (BacMam) are 
of interest for numerous reasons as described above. This method of gene delivery has been 
previously established in the lab for transient delivery of transgenes as the efficiency is much 
higher than transfection and it is much less cytotoxic. Also the commercial vectors allow easy 
insertions of the gene of interest by Gateway cloning (Figure 24 A). While this works for 
transient expression, BacMam is unable to establish stable cell lines as the virus neither integrates 
nor replicates in mammalian cells. If we wanted to use BacMam in our model cell line for the 
intestinal epithelium, T84 cells, we require a stable cell line as their low transduction efficiency 
and their slow growth after selection creates a timeframe during which transient expression is lost 
(Figure 24 C). Also other model systems used in our lab would benefit from a viral vector with 
such a high cargo capacity, e.g. primary human tissue grown in three dimensional culture (human 
intestinal organoids). To that end, we decided to modify the commercial BacMam backbone so it 
can be stably maintained in mammalian cell lines. 
To create a persisting BacMam vector, we inserted a self-cleaving peptide sequence from 
porcine teschovirus-1 (P2A) followed by the puromycin resistance gene and the S/MAR 
sequence behind the Gateway cloning cassette (Figure 24 B). When the target gene is translated 
the P2A peptide will cleave it into two functional proteins allowing for puromycin selection of 
cells expressing the transgene (Figure 24 B). The S/MAR sequence will anchor the vector DNA 
to the nuclear matrix making sure it will be replicated and remain mitotically stable. The S/MAR 
sequence was PCR amplified from an existing plasmid (pMAX-SMAR-GFP-P2A-Puro). The 
existing BacMam pCMV-DEST backbone was amplified as well creating a linearized amplicon 
opening up the plasmid between the Gateway cassette and the WPRE sequence. The S/MAR 
containing PCR product was inserted into pCMV-DEST by NEBuilder HiFi Assembly. When a 
transgene is inserted into this new BacMam S/MAR plasmid, a large mRNA containing the gene 
of interest, the puromycin resistance gene and the S/MAR sequence will be transcribed. 
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Figure 24: Creation of backbone for recombinant baculoviruses.  A) Schematic of the commercial BacMam vector pCMV-
DEST with Gateway cloning cassette (top) and as a GFP expression vector (bottom). B) Schematic of the newly created BacMam 
vector with puromycin resistance gene and S/MAR sequence. The empty vector with the Gateway cloning cassette is depicted on 
top of an example vector for GFP expression. mRNA and protein produced by either vector are depicted in blue and green 
respectively. C-F) FACS analysis following GFP expression in HEK 293T cells transduced with the commercial BacMam or the 
new BacMam S/MAR. C) Cells were transduced with commercial BacMam backbone not carrying the S/MAR sequence or 
selection marker. Continued on page 73 
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Continued from Figure 24. D) Cells transduced with new BacMam S/MAR that were not selected with puromycin. E) Cells 
transduced with BacMam S/MAR were kept under selection with 1 µg/ml puromycin for the duration of the experiment. F) Cells 
with BacMam S/MAR were selected with 1 µg/ml puromycin for one week and cells kept without selection pressure for the rest 
of the experiment. One week after puromycin removal expression was measured for the first time. CMV-IE1: Cytomegalovirus 
immediate early promoter; attR1/attR2: recombination sites for Gateway LR reaction; ChlorampR: Chloramphenicol resistance 
gene; ccdB: kill gene encoding CcdB gyrase poison; WPRE: Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element; 
pA: polyadenylation signal; GFP: green fluorescent protein; P2A: porcine teschovirus self cleaving peptide; PuroR: puromycin 
resistance gene; S/MAR: scaffold/matrix attachment region. 
The new BacMam S/MAR plasmid was tested by cloning GFP into it, producing viral 
vectors, and using it to transduce HEK 293T cells. BacMam expressing GFP from the original 
backbone, without the S/MAR or a selection marker, was used to transduce cells in parallel 
(Figure 24 C). Two days after transduction virus containing medium was replaced with fresh 
medium. Cells transduced with BacMam without S/MAR and one sample of BacMam with 
S/MAR were left without selection to test if S/MAR alone was sufficient to keep GFP expression 
longer compared to the parental backbone (Figure 24 C and D). Two samples were selected with 
1 µg/ml puromycin. One was kept under selection the whole time (Figure 24 E) and the other was 
selected for only one week and passaged without puromycin for the remaining time (Figure 24 
F). Cells transduced with either virus expressed GFP proving that both are functional. Cells 
transduced with BacMam without the S/MAR sequence lost expression quickly. By week three 
only 8% of cells still expressed GFP. After six weeks only 1.5% of cells still expressed GFP 
(Figure 24 C). BacMam expressing the S/MAR sequence mostly lost expression without 
puromycin selection. Beginning at week three, between 1% and 10% expressed GFP. The low 
number of expressing cells fits well with reports that only 1-5% of CHO cells transfected with 
S/MAR plasmids stably anchor and maintain them138. When cells transduced with BacMam 
S/MAR were selected with puromycin, over 95% of cells kept expressing GFP over the course of 
32 weeks proving that the puromycin resistance gene as well as the S/MAR sequence are 
functional and allow the establishment of stable cell lines (Figure 24 E). When after initial 
selection the puromycin is removed, the percentage of GFP expressing cells remains stable at 
around 70% indicating that once the extrachromosomal DNA is stably anchored selection 
pressure can be removed without losing expression (Figure 24 F). Together, these results show 
that we succeeded in modifying BacMam to express a selection marker and an S/MAR sequence 
allowing the DNA to be maintained over at least 32 weeks.  
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3.4.2 BACMAM REPORTER 
Now we wanted to utilize the newly created BacMam S/MAR vector. We decided to 
design a new backbone for reporter constructs. The existing Gateway cassette was replaced with 
mCherry so that all reporter cells will have constitutive mCherry expression (Figure 25 A and B). 
The Gateway cassette was moved upstream of the CMV promoter thereby lacking a promoter. In 
this configuration, Gateway cloning can be used to insert a promoter reporter, e.g. an IFNβ 
promoter driving expression of luciferase (Figure 25 C). 
 
Figure 25: Schematic of the BacMam reporter. A) The new BacMam S/MAR construct. B) BacMam S/MAR was modified to 
constitutively express mCherry and the puromycin resistance gene. The Gateway cloning cassette was moved upstream without a 
promoter. C) Same as B except with the IFN beta promoter driving luciferase expression. mRNAs and proteins produced are 
shown below in blue and green respectively. The dashed lines symbolize expression that depends on reporter activity. CMV-IE1: 
Cytomegalovirus immediate early promoter; attR1/attR2: recombination sites for Gateway LR reaction; ChlorampR: 
Chloramphenicol resistance gene; ccdB: kill gene encoding CcdB gyrase poison; WPRE: Woodchuck Hepatitis Virus 
Posttranscriptional Regulatory Element; pA: polyadenylation signal; GFP: green fluorescent protein; P2A: porcine teschovirus 
self cleaving peptide; PuroR: puromycin resistance gene; S/MAR: scaffold/matrix attachment region. 
A BacMam vector with the IFNβ reporter and a firefly luciferase reporter was used to 
transduce HEK 293T cells. Cells were kept under selection and expressed mCherry for several 
months. After about six months, we checked the percentage of reporter positive cells by flow 
cytometry for mCherry. In line with the results of the BacMam S/MAR vector (Figure 24 E) 
100% of the cells expressed mCherry (Sup. Figure 9). Next we wanted to verify that the cells do 
not only express mCherry but have a functional IFNβ reporter. Therefore we transiently 
transduced HEK 293T cells and infected them with reovirus two days later or infected the HEK 
293T cell line stably expressing the reporter construct for six months. Both cell lines show a 
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significant induction of luciferase expression when tested 24 hours post reovirus infection (Figure 
26). These experiments show that we successfully modified a BacMam expression vector to 
express a selection marker and an S/MAR sequence allowing for establishment of stable cell lines 
(Figure 24). Additionally, we further modified this new BacMam vector to allow easy cloning of 
reporter cassettes using the Gateway system (Figure 25) and verified its functionality (Figure 26). 
 
 
Figure 26: BacMam IFNβ luciferase reporter in HEK 
293T cells. Wildtype HEK 293T cells transiently transduced 
with BacMam IFNβ reporter for 48 hours (white box) or 
HEK293T cells stably expressing the IFNβ reporter for six 
months were infected with reovirus. 24 hours post reovirus 
infection luciferase values were measured. Three independent 
experiments with standard deviation are shown. The relative 
luminescence of non infected and infected cells was compared 
using an unpaired, two-tailed t-test with P > 0.05; * = P ≤ 
0.05; ** = P ≤ 0.01; *** = P < 0.001. 
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4 DISCUSSION 
4.1 PHOSPHOINOSITIDE PROJECT 
The main objective of this thesis was to elucidate the role of endosomal PI(3)P in 
establishing and maintaining polarity as well as in immune signaling. PI(3)P is reported to be the 
predominant phosphoinositide in early endosomes146. We could verify this localization in our 
intestinal epithelial cells where PI(3)P showed a strong overlap with the early endosome marker 
EEA1 (Figure 5 B). We originally used specific inhibitors of VPS34, the main source of 
endosomal PI(3)P, to determine the role of PI(3)P on cellular polarization and immune 
induction147,148. First we determined the amount of inhibitors needed to remove PI(3)P from the 
endosomes. We showed that 1 µM of two selected inhibitors clearly reduced but not completely 
removed endosomal PI(3)P in T84 cells (Figure 6 and Figure 7). When either 5 µM VPS34-IN1 
or 6 µM SAR405 were used, the endosomal PI(3)P staining was completely lost (Figure 6 and 
Figure 7). Our result that 1 µM VPS34-IN1 significantly reduces but not completely removes 
PI(3)P fits well with published data148. 1 µM SAR405 on the other hand did not seem have any 
residual PI(3)P in the original publication147. This difference between our data and the published 
data could be due to the different cell lines used. As expected, the higher concentrations worked 
better for both inhibitors and removed PI(3)P completely (Figure 6 and Figure 7). Both inhibitors 
shared their quick mode of action and long lasting effect. Even after 24 hours the PI(3)P pools 
did not reappear at either concentration. The IC50 of SAR405 for other PI3-kinasese is over 10 
µM so 6 µM SAR405 should still specifically inhibit VPS34147. For VPS34-IN1 on the other 
hand results are not as clear. Depending on which lipid kinase panel was used, several class I and 
II PI3-kinases had IC50 values below 5 µM. We decided to continue with three different 
conditions. 6 µM SAR405 as it completely removes PI(3)P, does not inhibit other PI3-kinases, 
and was used in the related cell line Caco-2 to show the importance of VPS34 for epithelial 
integrity (Figure 7)103,147 For VPS34-IN1 both 1 µM and 5 µM were used. While 5 µM 
completely removes endosomal PI(3)P, it could potentially inhibit other kinases as well (Figure 
6)148. To avoid the possibility of off-target effects we included 1 µM VPS34-IN1 at the risk of 
insufficient removal of PI(3)P. 
Having established the inhibitor is functional, we continued by assessing its impact on 
polarization. As described in the introduction, there is a strong link between tight junctions and 
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polarity. Tight junction formation can be followed over time by measuring the trans-epithelial 
electrical resistance (TEER). Treating T84 wildtype cells with 1 µM VPS34-IN1 had an effect on 
polarization (Figure 9 and Sup. Figure 2). If added at day one, polarization progressed slower as 
seen by the longer time needed to reach 1000 Ω (Figure 9 and Sup. Figure 2 A and C). The same 
delayed polarization could be seen when the inhibitor was added after three days. Addition of the 
inhibitor at day six, when the cells were fully polarized, again resulted in an abrupt slow down of 
polarization. Treatment with 5 µM VPS34-IN1 showed the same phenotype seen with 1 µM but 
the phenotype was even more pronounced (Figure 10 and Sup. Figure 3). Addition of inhibitor at 
day one prevented polarization as cells even after nine days did not reach 1000 Ω. If added after 
three days cells did polarize but the values were much lower than in the mock control. Also 
TEER values decreased over time ending up below 1000 Ω when the timecourse ended at day 
nine. If cells were already polarized when the inhibitor was added it resulted in an abrupt and 
drastic decrease in TEER values. Lastly we tested polarization with 6 µM SAR405 (Figure 11 
and Sup. Figure 4). Similar to VPS34-IN1, treating cells with SAR405 from day one prevents 
normal polarization. Only at the end of the timecourse, when the TEER control cells peaked, 
TEER values reached 1000 Ω. When the inhibitor was added after three or six days, the results 
were very similar to 1 µM VPS34-IN1 (Figure 9 and Sup. Figure 2). To exclude that the 
decreased TEER resulted from holes in the monolayer due to cell death, we stained the nuclei 
with DAPI at the end of the timecourse. Cells still formed monolayers when the inhibitor was 
added at day three or later (Figure 12). This showed us that neither delayed TEER development 
nor a significant drop in TEER was due to cell death. Since cells still formed monolayers but the 
TEER was reduced we assume that the tight-junctions are impaired which is indicating a problem 
with polarization upon inhibitor induced PI(3)P depletion as was published103. PI(3)P recruits the 
protein WDFY2 which then negatively regulates LKB1. Loss of PI(3)P or VPS34 results in 
increased LKB1 phosphorylation and activation of AMPK, a pathway that has been known to be 
involved in tumor development and epithelial polarity103,179. Furthermore it is interesting, that 
Arp2/3 has been shown to mediate the polarized distribution of PAR6 in C. elegans104. Arp2/3 in 
turn is regulated by the WASH complex that can bind to PI(3)P and PI(3,5)P2
180. PAR6 is known 
to regulate polarity and formation of tight junctions and misregulation results in lower TEER 
values181. 
Discussion 
78 
 
Next we wanted to use the VPS34 inhibitors to investigate the role of PI(3)P in immunity. 
Over the last years, a role for the intestinal virome in health and disease has become clear. Links 
between the intestinal virome, Crohn’s disease and ulcerative colitis have been found182,183. It was 
also shown that murine norovirus (MNV) can replace the microbiome in germ-free mice184. 
MNV re-established normal intestinal morphology, partially protected the mice from chemically 
induced intestinal damage, and improved symptoms of Citrobacter rodentium infection184. 
Therefore we decide to use reovirus, a commonly used model for enteric viruses, to evaluate the 
role of PI(3)P in detecting and propagating an immune response after viral infection. From 
experiments in our lab, we know that reovirus efficiently infects T84 cells (Figure 2)159,161. 
Reovirus has a double stranded RNA genome (dsRNA). After entry the virion is trafficked 
through early and late endosomes before it escapes into the cytoplasm. Reovirus is recognized by 
TLR3 and RLRs159,185,186. Because early to late endosome maturation and TLR3 signaling both 
utilize endosomal PI(3)P reovirus infection is a relevant model for our purposes. As described in 
the results section, we chose IFNλ, IL-6, and IL-8 as readouts as they are relevant in intestinal 
epithelia cells and expressed by T84 cells upon reovirus infection (Figure 14 and Figure 
15)103,160,162–164. 
While we knew that both PI(3)P inhibitors worked very fast (Figure 6 and Figure 7), we 
wanted to test if cells need to be pre-treated prior to infection. Also we wanted to establish 
whether to harvest samples after 16 or 24 hours (Figure 13). To that end T84 cells were either 
mock treated or pre-treated with 5 µM VPS34-IN1 for one hour. Afterwards cells were infected 
with or without 5 µM VPS34-IN1 for 16 and 24 hours. As expected, IFNλ, IL-6 and IL-8 were all 
produced upon reovirus infection and harvesting at 24 hours post infection yielded higher 
quantities. Treatment with 5 µM VPS34-IN1 resulted in a reduced immune response for all three 
readouts (Figure 13). Pre-treatment with VPS34-IN1 did not improve this phenotype which fits 
very well with the observation that endosomal PI(3)P is already removed after 15 minutes (Figure 
6). Contrary to PI(3)P depletion by 5 µM VPS34-IN1, SAR405 treatment resulted in significantly 
increased IFNλ, IL-6, and IL-8 production. While it contradicts our results for 5 µM VPS34-IN1, 
an increased IL-6 production upon TLR4 and TLR1/2 stimulation in bone marrow-derived 
dendritic treated with 1µM VPS34-IN1 or SAR405 cells has been reported165. We wanted to 
exclude that the reduced response with 5 µM VPS34-IN1 was not due to off-target effects due to 
the relatively high inhibitor concentration. When we repeated the experiment with 1 µM VPS34-
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IN1 we did not observe any changes in IFNλ, IL-6, or IL-8 levels upon infection. The fact that 1 
µM VPS34-IN1 does not change the immune response but 5 µM shows and effect, could either 
be due to insufficient removal of PI(3)P with 1 µM VPS34-IN1 or off-target effects with 5 µM 
VPS34-IN1 (Figure 6)148. Taken together, the discrepancy between the two inhibitors makes it 
impossible to make assumptions about the role of PI(3)P in the immune response to reovirus in 
T84 cells. Conflicting publications make it even more difficult to determine which phenotype is 
correct. One publication showed that VPS34 inhibition increased the immune response TLR4 
stimulation while another identified the PI(3)P effector WDFY1 as an adaptor in TLR3/4 
signaling which would argue for attenuated signaling upon VPS34 inhibition109,165. To further 
clarify which phenotype is correct, we have to use other VPS34 inhibitors, e.g. VPS34 inhibitor 1 
(Compound 19, PIK-III analogue) or autophinib187,188. 
Finally we showed that the relative infectivity of reovirus was reduced in T84 cells treated 
with both VPS34 inhibitors (Figure 16). This would fit nicely with the role of PI(3)P in endosome 
maturation and the requirement of reovirus to traffic from early to late endosomes before entering 
the cytoplasm and replication86,185. More experiments will be necessary to clarify the role of 
VPS34 and PI(3)P in reovirus infection. 
As the inhibitors could give rise to off target effects and provided conflicting results we 
moved to a new method to modify endosomal PI(3)P levels by knocking down PI(3)P 
metabolizing enzymes. The major player in early endosome PI(3)P metabolism are VPS34 
(Figure 6 and Figure 7) and MTM191. Of the shRNAs tested against both proteins, all but one 
(shVPS34 #1) reduced mRNA levels to 30% or less compared to the scrambled control (Figure 
17 A). Cell lines expressing shMTM1 #1 and shVPS34 #3 were chosen to continue. They kept 
their knock-down on the RNA and protein level showing us that the knock-down cell lines were 
successfully established (Figure 17 B and C). These cell lines were used to test both polarization 
and immune response. As before, knock-down cell lines were seeded on transwell inserts and the 
TEER development was followed over nine to ten days (Figure 18). TEER values of scrambled 
control cells developed as wildtype cells (e.g. Figure 9 A). Interestingly, knock-down of VPS34 
changed TEER development. While cells did not polarize much slower, indicated by the time 
they reached 1000 Ω, their TEER developed slowed down afterwards and stayed lower (Figure 
18). This fits well with the observations made in the inhibitor treated cells that did not reach as 
high TEER values (Figure 9, Figure 10, and Figure 11). The stronger effect of 5 µM VPS34-IN1 
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or 6 µM SAR405 most likely reflects a more efficient PI(3)P depletion, especially when added at 
day one where it prevents cells from forming a full monolayer (Figure 12). When the inhibitor 
was added at later times the results are very similar compared to the VPS34 knock-down. It is 
still surprising to see that polarization is not impaired given that MTM1 mutations in humans are 
associated with x-linked myotubular myopathy (XLMTM). Cell lines derived from these patients 
show increased PI(3)P levels and defective exocytosis which points toward trafficking defects78. 
These cells have an intracellular accumulation of β1-integrin which in polarized epithelial cells is 
required for establishing apico-basal polarity. The same intracellular aggregation of β1-integrin 
can be seen in MTM1 knock-down HeLa cells78. This either means that trafficking of β1-integrin 
in these cells differs from T84 cells or the β1-integrin levels at the plasma membrane are still 
high enough to induce polarization. This could be tested by comparing intracellular and cell 
surface levels between the knock-down cell lines. Knock-down of MTM1 did not lead to major 
differences compared to the scrambled control (Figure 18). This indicates that an increase of 
PI(3)P does not further improve polarization. In order to verify that, an immunostaining of PI(3)P 
levels in the knock-down cell lines needs to be performed. However, as the knock-down worked 
efficiently (Figure 17) and VPS34 is the main source of endosomal PI(3)P (Figure 6 and Figure 
7) it is very likely that PI(3)P levels are reduced. 
As with the inhibitor treated cells we wanted to test the immune response to reovirus 
infection. Cells were infected with reovirus one day after seeding and samples harvested 24 hours 
post infection (Figure 19). The IFNλ response is significantly increased in MTM1 knock-down 
cells while it is significantly decreased upon VPS34 knock-down (Figure 19 A and B). One 
possible explanation is the PI(3)P binding sorting adaptor WDFY1109. Another, and even more 
intriguing, explanation is based on TLR3 signaling through two different pathways. TLR3 can 
signal via TRIF, TRAF6, RIP1, TAK1 and NF-κB which leads to the production of 
proinflammatory cytokines42. Signaling via TRIF, TRAF3, TBK1/IKKi drives IRF3 mediated 
interferon production42. Interestingly it was shown that PI(5)P produced by PIKfyve binds TBK1 
and IRF3 to mediate IRF3 phosphorylation and activation189. This enhances downstream 
signaling, e.g. IFNβ production189. NF-κB mediated cytokine production on the other hand was 
not influenced by PIKfyve and PI(5)P. This was true for TLR3 and TLR4 signaling and therefore 
argues for a general method of IRF3 regulation independent of the receptor the signal originally 
comes from. This is particularly interesting since RLRs signal via IRF3 and NF-κB as well190. 
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And while the role of phosphoinositides in innate immunity is normally investigated for TLRs 
this offers an intriguing mechanism of how phosphoinositides can regulate RLR signaling as 
well. While it is known that PIKfyve is the kinase producing most of the PI(5)P, the exact 
pathway is under debate. A direct phosphorylation of phosphatidylinositol is one option. But 
since it is known that PIKfyve makes PI(3,5)P2 from PI(3)P it is possible that at least some of the 
cells PI(5)P is produced through an PI(3,5)P2 intermediate and subsequent dephosphorylation by 
a 3-phosphatase191. The latter pathway is interesting since it would link PI(3)P to PI(5)P and 
thereby to IRF3 mediated interferon production through diverse receptors including RLRs. This 
could explain the IFNλ response seen (Figure 19). Knock-down of MTM1 increases PI(3)P levels 
which could shift the equilibrium toward higher PI(3,5)P2 and PI(5)P concentration increasing the 
IFNλ response. Also MTM1 has been shown to dephosphorylate PI(3,5)P2 in vitro to produce 
PI(5)P178. Knock-down of VPS34 on the other hand reduces the PI(3)P level and thereby PI(5)P 
which would explain the lowered response. To verify the higher or lower IRF3 activation levels 
in MTM1 and VPS34 knock-down cell lines respectively one could analyze IRF3 
phosphorylation levels or relocalization of activated IRF3-GFP into the nucleus157. However, this 
pathway could not explain the IL-6 and IL-8 responses seen as both are produced NF-κB-
dependent pathways and should therefore not be affected192–194. 
MTM1 knock-down increases the IL-6 response while VPS34 knock-down does not have 
any impact. IL-8 on the other hand seems to be reduced in both knock-downs (Figure 19). Since 
they are both produce in an NF-κB-dependent pathway they should behave similar. As this is not 
the case, their signaling cascades might differ in certain components making it more or less 
susceptible to changed PI(3)P levels. It was published that Rac1 and Cdc42 regulate IL-8 
secretion in MDCK cells while NF-κB and MAP kinase signaling is not imparied195. Both Rac1 
and Cdc42 are parts of the epithelial polarity program and PI(3)P is linked to polarity (Figure 9, 
Figure 10, Figure 11, and Figure 17)103. One could imagine that the differences seen in Figure 19 
are not due to differences in IL-8 production but secretion. ELISA analysis of cell lysates instead 
of supernatants could help to answer that question. Also one should keep in mind that knock-
down cells have reduced protein levels. Both MTM1 and VPS34 interact with various other 
proteins and it is perceivable that reduced MTM1 or VPS34 levels interfere with the correct 
function of one or more of their binding partners96,169. 
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Finally we wanted to use a more advanced method of manipulating endosomal PI(3)P by 
utilizing chemically induced dimerization (CID) (Figure 20). The major advantage of this system 
is the spatio-temporal control. This is especially important because inhibition and knock-down 
target both the autophagy and endosome associated VPS34 complexes indiscriminately96,147. We 
chose a Rab5 anchor for early endosomes and the PI(3)P phosphatase MTM1 either as full-length 
wildtype enzyme or the phosphatase-dead C375S mutant as the players for our system (Figure 
20)175,176. Furthermore we chose to use a mutated form of the FRB domain, FRB*, as it allows us 
to use a rapalog instead of rapamycin which would interfere with endogenous mTOR, a central 
regulator of metabolism174,196.  
To verify loss of PI(3)P upon recruitment of MTM1 wildtype, we would ideally use an 
anti-GFP antibody (Figure 5 A) but as the Rab5 anchor is fused to GFP, this is not an option 
(Figure 20). Additionally, due to our cellular system, transfecting a fluorescently tagged PI(3)P 
sensor was not a viable option (Sup. Figure 1). Therefore, we chose to use an indirect method 
based on morphology. It was reported that endosomes become enlarged or tubularized upon 
PI(3)P depletion which we confirmed in the easily transfectable HEK 293T cells171,177. When 
MTM1 wildtype is recruited to early endosomes they lose their PI(3)P and change morphology 
(Figure 21 A). MTM1-C375S on the other hand is recruited but does not change PI(3)P levels or 
endosome morphology (Figure 21 B). Since VPS34 inhibition also induces enlarged endosomes 
(Figure 21 C), we assume that this change is due to loss of PI(3)P and not induced by rapalog or 
recruitment of MTM1 itself. In fact, when we use our T84 cell line expressing the Rab5-GFP 
anchor and MTM1 wildtype we can see the same changes in endosome morphology indicating 
that the system works in T84 cells (Figure 21 D). 
To test the impact of PI(3)P on polarization in this inducible system, we followed the 
same protocol as during the inhibitor treatment but added rapalog instead of VPS34 inhibitors 
(Figure 8 C). We compared the effect between T84 cell lines expressing a Rab5 anchor and either 
MTM1 wildtype or MTM1-C375S with normal T84 wildtype cells (Figure 22). Addition of 
rapalog one day post seeding prevented polarization. As this is the case in MTM1-C375S and 
wildtype cells, it is not due to loss of PI(3)P but to off target effects of the rapalog. Adding 
rapalog at later times also interfered with polarization. While cells still polarized, TEER > 1000 
Ω, it was clearly slowed down or even decreased. Unfortunately this was true in all three cell 
lines indicating that the observed phenotype was again due to rapalog treatment itself. We further 
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checked the immune response in all three cell lines with or without rapalog (Figure 23). Rapalog 
reduced the immune response independent of the cell line used. Together with the observations of 
polarization, this further strengthens the argument that rapalog interferes with normal T84 cell 
function and is not usable for our purpose. Interestingly there are some significant differences in 
the immune response between the cell lines without rapalog, i.e. lower IFNλ expression in 
MTM1-C375S cells than in T84 wildtype cells and reduced IL-6 production in MTM1 wildtype 
and MTM1-C375S compared to T84 wildtype cells (Figure 23). Such differences might be 
explained by the fact that we are overexpressing full-length MTM1. It is perceivable that the full 
length enzyme, wildtype and C375S, can interact with their endogenous binding partners 
mimicking a normal protein overexpression even without inducing dimerization. It was shown 
that when MTM1-C375S and MTM1 wildtype are overexpressed in HEK 293T cells, MTM1-
C375S increases PI(3)P levels relative to MTM1 wildtype175. Interestingly, is has been shown 
that MTM1 can dephosphorylate PI(3,5)P2. The resulting PI(5)P induces MTM1 to form a 
heptameric ring which acts as an allosteric acitivator178. MTM1-C375S can form this ring 
together with wildtype proteins increasing their activity. This could explain how even a 
catalytically dead enzyme can change the cellular response, e.g. lower IL-6 response in both 
MTM1 wildtype and MTM1-C375S. One step to avoid such potential problems in the future 
would be the use of a truncated protein. However, a larger problem with this system is the 
dimerizer itself and in order to use a chemical dimerizer system we first need to find a dimerizer 
lacking cellular targets. One option would be the reversible chemical dimerizer rCD1197. While 
having slightly slower kinetics, it would give us the option to remove MTM1 from the 
endosomes with addition of FK506 (Tacrolimus). Still one should keep in mind that FK506 itself 
is an immunosuppressant that binds to FKBP to inhibit calcineurin and has to be tested for its 
impact on T84 polarity and immunity198.  
During this project we could verify a role of VPS34 and PI(3)P in cellular polarization by 
using inhibitors or knock-down. This fits with recently published results regarding the role of 
VPS34 in maintaining epithelial integrity103. The impact on immunity is less clear due to 
conflicting results of the two VPS34 inhibitors used. The results in our knock-down cell lines are 
interesting, especially the impact on IFNλ which fits well with the link between PI(3)P, PI(5)P 
and IRF3 mediated interferon expression. The results regarding IL-6 and IL-8 are unfortunately 
not as clear and will require further investigation. Furthermore we managed to establish a 
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chemically induced dimerization system in T84 cells and verify its functionality. Unfortunately, 
while being a very promising approach, the side effects of rapalog keep us from using it for now. 
If another dimerizer is found that does not interfere with our cells and if truncated enzymes are 
used this could become a fantastic tool allowing us to dissect the role of individual 
phosphoinositides in polarity and immunity with an unprecedented spatio-temporal control.  
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4.2 BACMAM PROJECT 
The goal of this project was to establish a persisting BacMam vector using an S/MAR 
sequence. We modified a commercial BacMam that is already used in our lab and allows us 
efficient cloning with the Gateway system (Figure 24 A). We inserted the puromycin resistance 
gene downstream of the Gateway cloning cassette (Figure 24 B), and a self-cleaving P2A 
sequence from porcine teschovirus-1 allowing us to split the protein of interest from the 
resistance gene upon translation. Further downstream we inserted the S/MAR sequence 
facilitating the episomal maintenance128. We chose this method as it does not require expression 
of a viral oncogene or integration into the host cell genome and should therefore have a better 
biosafety profile120,122–124. Also the S/MAR sequence has been suggested to prevent epigenetic 
silencing of the CMV promoter and specifically links the plasmid to nuclear compartments in 
which active transcription takes place138,139. We then transduced HEK 293T cells with viral 
vectors expressing GFP either from the original backbone without S/MAR (Figure 24 C) or from 
the new S/MAR backbone (Figure 24 D-F). As expected, cells transduced with the commercial 
BacMam lost expression within two to three weeks (Figure 24 C)123. Only a few percent of cells 
transduced with BacMam S/MAR without selection kept their expression (Figure 24 D). This was 
not unexpected as it was reported that only between one and five percent of CHO cells 
transfected with an S/MAR plasmid will maintain it129,137,138. When cells were kept under 
constant selection, within a short time all cells expressed GFP and kept expression for over 30 
weeks (Figure 24 E). To verify the report that no selection pressure is required for maintenance of 
S/MAR plasmids once they are stably anchored, we removed the selection pressure from one 
sample after one week (Figure 24 F)129,137,138. Indeed we can see that the S/MAR sequence 
maintains the vector. Between 60 and 80 percent of cells keep expressing GFP for over 30 weeks. 
The lower percentage of GFP positive cells compared to cells under constant selection indicates 
that not all cells had stably anchored the vector DNA at the time the selection pressure was 
removed (Figure 24 E and F). 
Next we wanted to modify the BacMam S/MAR vector to allow expression of reporter 
constructs. Therefore we moved the Gateway cloning cassette upstream of the CMV promoter 
and inserted mCherry between the CMV promoter and the puromycin resistance gene (Figure 25 
B). This construct allows us easy cloning of reporters into the promoterless Gateway cassette, 
antibiotic selection and tracking of transduced cells through mCherry expression. To test the 
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construct we cloned a firefly luciferase driven by an IFNβ promoter (Figure 25 C). This construct 
was used to make stable HEK 293T cell lines which kept expression for about six months (Sup. 
Figure 9). This cell line and HEK 293T cells transiently transduced with the same BacMam 
vector were infected with reovirus and the luciferase activity measured (Figure 26). Both, 
transient and stable expressing cells, showed a clear induction of the IFNβ reporter upon infection 
proving the BacMam reporter construct is functional.  
Taken together these results show that we successfully created a persistent BacMam and 
further modified it to allow for reporter gene expression (Figure 24 B and Figure 25). Both 
constructs are functional and were able to drive expression in HEK 293T cells for up to half a 
year (Figure 24 C-F, Figure 26, and Sup. Figure 9). This is, to our knowledge, the first time a 
persistent baculovirus vector is described that does not rely on integration or viral genes. Vectors 
established by others either use integration via the sleeping beauty transposon or AAV ITRs and 
the AAV rep gene or rely on the EBV origin of replication which requires expression of the viral 
oncogene EBNA1120,122–124. While an S/MAR sequence has been integrated into a baculovirus 
genome before, it did not result in prolonged expression, possibly due to the lack of antibiotic 
selection199. They also did not try to maintain the whole viral genome. The transgene was 
recombined into a minicircle, small circular DNA that is devoid of bacterial sequences and 
maintained via an S/MAR sequence200. This required simultaneous transduction with a second 
baculovirus199. 
Next we will have to verify that the vector really is maintained episomally and does not 
integrate. Also it has to be tested for stable expression in T84 cells or even human intestinal 
organoids. It would be interesting to further modify the reporter backbone by adding a second 
reporter for interferon stimulated genes (ISGs). This would allow us to follow both induction of 
interferon and the downstream signaling. This would be especially interesting in three 
dimensional cell culture, i.e. spheroids or human intestinal organoids. 
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6 SUPPLEMENTARY 
 
Sup. Figure 1: Transfection of T84 cells is not efficient. T84 cells were transfected with the PI(3,4)P2 sensor mRFP-TAPP1 
and were visualized 48 hours post-transfection by epifluorescence (left) or brightfield (right). Representative image is shown. 
 
Sup. Figure 2: T84 wildtype polarization with 1 µM VPS34-IN1. T84 cells were seeded onto transwell inserts and their 
polarization was monitored by TEER measurements. Cells were either mock treated (DMSO) or treated (black) with 1 µM 
VPS34-IN1 beginning at day 1, day 3, or day 6 post seeding (red) and kept with inhibitor for the remainder of the experiment. 
Three independent experiments are shown. For each condition two transwells were used and average and standard deviation are 
shown. 
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Sup. Figure 3: T84 wildtype polarization with 5 µM VPS34-IN1. T84 cells were seeded onto transwell inserts and their 
polarization was monitored by TEER measurements. Cells were either mock treated (DMSO) or treated (black) with 5 µM 
VPS34-IN1 beginning at day 1, day 3, or day 6 post seeding (red) and kept with inhibitor for the remainder of the experiment. 
Four independent experiments are shown. For each condition two transwells were used and average and standard deviation are 
shown. 
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Sup. Figure 4: T84 wildtype polarization with 6 µM SAR405. T84 cells were seeded onto transwell inserts and their 
polarization was monitored by TEER measurements. Cells were either mock treated (DMSO) or treated (black) with 6 µM 
SAR405 beginning at day 1, day 3, or day 6 post seeding (red) and kept with inhibitor for the remainder of the experiment. Two 
independent experiments are shown. For each condition two transwells were used and average and standard deviation are shown. 
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Sup. Figure 5: Knock-down in T84 cells requires low density cells and passaging. A) Experimental procedure for transient 
knock-down using AAVs. B) Knock-down of MDA5 on RNA level at each time when cells were passaged and re-transduced. C) 
Western blot analysis of the samples in B. D) Experimental procedure for lentiviral knock-down. E) RNA level of PTEN after 
several passages of cells at low density for over two weeks. F) Western blot analysis of PTEN protein levels in scrambled control 
(mock) or knock-down cells (PTEN). This data was taken from my own Master Thesis and has originally been created by myself. 
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Sup. Figure 6: T84 Rab5-GFP-FRB* + mRFP-FKBP-MTM1-wildtype polarization timecourses with rapalog. T84 cells 
expressing recruitable MTM1-wt were seeded onto transwell inserts and their polarization was monitored by TEER 
measurements. Rapalog was added at indicated time points and was maintained throughout the whole experiment. Three 
independent experiments with two transwells per timepoint are shown. Average and standard deviation are shown. 
Supplementary 
112 
 
 
Sup. Figure 7: T84 Rab5-GFP-FRB* + mRFP-FKBP-MTM1-C375S polarization timecourses with rapalog. T84 cells 
expressing recruitable MTM1-C375S were seeded onto transwell inserts and their polarization was monitored by TEER 
measurements. Rapalog was added at indicated time points and was maintained throughout the whole experiment. Three 
independent experiments with two transwells per timepoint are shown. Average and standard deviation are shown. 
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Sup. Figure 8: T84 wildtype polarization timecourses with rapalog. T84 WT cells were seeded onto transwell inserts and their 
polarization was monitored by TEER measurements. Rapalog was added at indicated time points and was maintained throughout 
the whole experiment. Four independent experiments with two transwells per timepoint are shown. Average and standard 
deviation are shown. 
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Sup. Figure 9: Gating for HEK 293T wildtype and BacMam p35-luc reporter cells. HEK293T cells were analyzed 6 months 
after transduction with the BacMam reporter. Gating for living cell population and mCherry expression for wildtype. (top panel) 
or HEK 293T cells transduced with BacMam p35-luc reporter (bottom panel). 
 
